

(A joi



Contents

Page

2

I A E F A

F A A L S 222

I A E F A E I 222



Financial Highlights

Income Statement

	2020 RMB' 000	For the reporting period ended December 31,			
		2018 B000	2018 B000	2017 B000	2016 B000
Revenue	1,031,284	863,622	745,722	666,436	415,088
Cost of sales	87,904	55,523	60,600	63,863	22,133
Gross profit	(28,949)	(17,901)	(31,411)	(20,227)	(26,588)
Operating profit	58,955	38,228	74,366	47,836	65,551
Profit attributable to shareholders	70,000	57,228	83,566	40,711	68,832
Other comprehensive income	(11,045)	(10,611)	(5,627)	(1,235)	(3,281)

	2020 RMB' 000	As of December 31,			
		2018 B000	2018 B000	2017 B000	2016 B000
Operating assets	2,248,947	2,117,352	1,803,724	1,603,011	1,033,382
Operating liabilities	934,523	855,843	635,451	573,014	560,122
Operating liabilities	1,314,424	1,261,509	1,052,273	1,104,477	1,041,300
Equity attributable to shareholders	1,211,846	1,164,484	1,103,555	1,051,834	1,008,383
Other comprehensive income	102,578	97,225	84,278	58,662	32,877

Chairman's Statement

Dear Shareholders,

As we have seen, the world has been facing the unprecedented challenges of the COVID-19 epidemic, the economic recession of

Management Discussion and Analysis

Business Review

Psychiatric Specialized Medical Service Industry in China

In the past few years, with the rapid development of people's living standards, the population aged 60 and above has increased significantly. According to the National Bureau of Statistics, in 2015, the number of people aged 60 and above reached 212 million, accounting for 15.5% of the total population. With the aging of the population, the demand for medical services has increased significantly. In particular, the demand for psychiatric specialized medical services has increased significantly. The government has also paid more attention to the development of the psychiatric specialized medical service industry. In 2016, the government issued the "Opinions on Deepening the Reform of the Medical Service System" (Guanyu Jiaqiang Xinwenguan Feiqing Shiqian Yanzhong Jingshen Zhanrang Huanzhe Zhiliao Guanli Gongzuo de Tongzhi) (Guidelines for Strengthening the Management Work of Treatment of Severe Mental Disorder Patients during the COVID-19 Epidemic Period), which clearly stated that the government will support the development of the psychiatric specialized medical service industry and encourage social capital to enter the industry. In addition, the government has also issued various policies to support the development of the psychiatric specialized medical service industry, such as providing tax incentives, reducing the burden of medical insurance payment, and increasing the investment in the industry. These policies have effectively promoted the development of the psychiatric specialized medical service industry in China.

At present, the demand for psychiatric specialized medical services is still in a stage of rapid growth. The demand for psychiatric specialized medical services is not only increasing in quantity but also in quality. Patients are more concerned about the safety and effectiveness of medical services. In addition, the demand for psychiatric specialized medical services is also increasing in terms of the types of services. Patients are not only seeking treatment for mental disorders but also seeking psychological counseling and rehabilitation services. These trends have further promoted the development of the psychiatric specialized medical service industry in China.

On April 17, 2021, the State Administration of Market Regulation issued the "Opinions on Deepening the Reform of the Medical Service System" (Guanyu Jiaqiang Xinwenguan Feiqing Shiqian Yanzhong Jingshen Zhanrang Huanzhe Zhiliao Guanli Gongzuo de Tongzhi) (Guidelines for Strengthening the Management Work of Treatment of Severe Mental Disorder Patients during the COVID-19 Epidemic Period). This document clearly stated that the government will support the development of the psychiatric specialized medical service industry and encourage social capital to enter the industry. In addition, the government has also issued various policies to support the development of the psychiatric specialized medical service industry, such as providing tax incentives, reducing the burden of medical insurance payment, and increasing the investment in the industry. These policies have effectively promoted the development of the psychiatric specialized medical service industry in China.

Management Discussion and Analysis

2020, the company incurred a loss compared to the corresponding period of the previous year. However, the company's performance is based on the corresponding period. Secondly, the company's operating results are affected by the change in the price of the raw materials. In addition, the company's operating results are also affected by the change in the price of the raw materials.

The change of the company's operating results is mainly due to the change in the price of the raw materials. The company's operating results are also affected by the change in the price of the raw materials. In addition, the company's operating results are also affected by the change in the price of the raw materials.

As a result, the company's operating results are affected by the change in the price of the raw materials. The company's operating results are also affected by the change in the price of the raw materials. In addition, the company's operating results are also affected by the change in the price of the raw materials.

Business Risks

2020, the company's business risks are mainly due to the change in the price of the raw materials. The company's business risks are also affected by the change in the price of the raw materials. In addition, the company's business risks are also affected by the change in the price of the raw materials.



Management Discussion and Analysis

(iii) The amount of the other significant activities in the form of operations, the cash flow and the other objectives of the practice in the before and after, the amount of the other

Management Discussion and Analysis

... of ...

... of ...

	For the year ended December 31,	
	2020 (RMB'000)	2019 (RMB000)
Treatment and general healthcare services		
... revenue	755,879	587,874
... of ...	506,496	441,786
... profit	249,383	146,088
Pharmaceutical sales		
... revenue	222,587	105,616
... of ...	194,544	174,318
... profit	28,043	31,298
Owned hospitals		
... revenue	978,466	733,400
... of ...	701,040	616,184
... profit	277,426	177,216

... of ...

Management Discussion and Analysis

In the reporting period, operating revenue of the Group (B133, Valid), reported an increase of 6% a compared in 2017, primarily due to the increase of operating income by 22.3% due to the decrease in the operating profit by 12.5%. The proportion of operating revenue to the total operating revenue of 13.7% (2017: 15.8%).

In the reporting period, the increase of both operating and non-operating income, the effect of the increase in the operating income by 28.6% a compared in 2017, due to the increase of 77.3% of the effect of the operating profit (2017: 74.1%); the effect of the operating income by 8.3% a compared in 2017, accounted for 22.7% of the effect of the operating profit (2017: 25%), of which: the ratio of operating income to operating revenue of 14.6% (2017: 16.5%), the ratio of operating income to operating revenue of 74.3% (2017: 76.1%).

One of the effects of the operating profit and the cost of operating income, the proportion of operating income to the total operating income, the proportion of operating income to the total operating income, the proportion of operating income to the total operating income, the proportion of operating income to the total operating income, the proportion of operating income to the total operating income, the proportion of operating income to the total operating income:

	For the year ended December 31,	
	2020 (RMB'000)	2017 (RMB'000)
Operating income	247,235	222,516
Operating profit	240,185	206,523
Operating profit of in-house	31,203	28,800
Operating profit of subsidiaries	75,906	62,804
Operating profit	42,653	35,000
Operating fee	24,081	17,325
Operating	39,777	41,216
Cost of revenue of owned hospitals	701,040	616,184

In the reporting period, the cost of revenue of the Group (B10, Valid), reported an increase of 13.8% a compared in 2017, primarily due to the increase in the operating profit of the Group. The increase of the cost of revenue is due to: (i) the increase of 11.1% in the operating profit of the Group; (ii) the increase of 16.3% in the operating profit of the Group; (iii) the increase of 4.5% a compared in 2017; and (iv) the increase of 1.1% a compared in 2017, primarily due to the increase in the operating profit of the Group.

Management Discussion and Analysis

For the consolidated period, the proportion of pharmaceuticals contribution to the consolidated revenue of the company increased to 35.3% (2019: 36.1%). The proportion of the professional services contribution to the consolidated revenue increased to 34.3% (2019: 33.5%). The proportion of the provision of insurance services contribution increased to 15.3% (2019: 15.0%). For the period, the economic cycle and financial conditions are of 2019.

Revenue of the insurance business

The revenue of the insurance business of the company in the period of the revenue of the insurance business, the revenue of the pharmaceuticals and medical services revenue of the revenue of the professional services, etc. For the period, the revenue of the insurance business of the company is B38.1 billion, of which the revenue of the pharmaceuticals and medical services revenue is B16.8 billion (2019: B21.7 billion); the revenue of the pharmaceuticals and medical services is B12 billion.

Revenue of the professional services

The revenue of the professional services of the company in the period of the revenue of the professional services, etc. For the period, the revenue of the professional services increased to B14.7 billion (2019: B3.7 billion), of which the revenue of the professional services of the company is B3.6 billion for the period of the professional services (2019: B32.6 billion).

Gross Profit and Gross Profit Margin

For the period, the gross profit of the company is B82.6 billion, representing an increase of 480% compared to 2019. The gross profit of the pharmaceuticals and medical services is B277.4 billion, representing an increase of 56.5% compared to 2019. The main reason for the increase of the gross profit is the increase of the pharmaceuticals and medical services:

	For the year ended December 31,	
	2020	2019
Pharmaceuticals and medical services	33.0%	24.9%
Pharmaceuticals and medical services	12.6%	15.2%
Owned hospitals businesses	28.4%	22.3%
Professional services	47.6%	4.5%
Consolidated gross profit margin	29.3%	23.8%

For the period, the contribution of the gross profit of the pharmaceuticals and medical services is 8.1 percentage points compared to 2019. The gross profit of the pharmaceuticals and medical services increased by 2.6 percentage points compared to 2019.

Management Discussion and Analysis

Tax and Surcharge

The company's tax and surcharge expense for the period ended B5.4.2019 (B5.2.2019).

Management Discussion and Analysis

Finance Expenses – Net

The net finance cost for the reporting period, after finance income from the sale of, borrowings, the expense of available for sale of the recovery of the net asset value of the company, the expense of the available for sale of the reporting period.

Management Discussion and Analysis

Gains from Change in Fair Value

In the reporting period, the fair value gains decreased to RMB6.6 million, mainly due to the decrease in the fair value of other derivatives.

Credit Impairment Losses

In the reporting period, credit impairment losses decreased to RMB23.1 million (2019: RMB21.3 million). The impairment losses for accounts receivable were RMB23.3 million (2019: RMB21.4 million), accounts for 2.3% of the total assets (2019: 2.4%). As at December 31, 2020 and 2019, the provision for bad debts of accounts receivable of the company were RMB0.3 million and RMB1.4 million, respectively, accounts for 0.3% and 7.1% of the total accounts receivable of the company. The collection rate continued to improve.

Asset Impairment Losses

In the reporting period, asset impairment losses were RMB0 million, mainly due to the impairment of goodwill arising from the acquisition of Beijing Jintan (Group) Co., Ltd. in the reporting period.

Non-Operating Income (Expenses)

The non-operating income mainly consisted of other income, and the non-operating expenses mainly consisted of other expenses and other disposal of derivatives. The above items are mainly related to the non-operating income and non-operating expenses for reporting period:

	For the year ended December 31,	
	2020 (RMB'000)	2019 (RMB'000)
Recovery of collateral of other assets	-	25,666
Other income	59	2,755
Non-operating income	850	2,681
Non-operating income	909	2,338
Loss of disposal of derivatives	436	13,200
Other expenses	8,537	2,877
Non-operating expenses	1,928	3,486
Non-operating expenses	10,902	12,713

In the reporting period, the non-operating income of the company decreased to RMB9 million, mainly due to the decrease of other income. The recovery of collateral of other assets of Beijing Fintan (Group) Co., Ltd. in the reporting period; in the reporting period, the non-operating expenses of the company decreased to RMB10 million, mainly due to the decrease of other disposal of derivatives.

Management Discussion and Analysis

Income Tax Expense

The reported income tax expense decreased to \$28.1 million (2023: \$17.3 million), representing a decrease of 67.4% as compared to 2023. As a result of 2024, our effective tax rate decreased to 32.1%, compared to 31.1% in 2023.

Goodwill

Inventory

As of December 31, 2024, the ending balance of inventory was \$37.5 million (as of December 31, 2023: \$23.6 million),

Management Discussion and Analysis

Investment Properties

As of December 31, 2022, the balance of investment properties is \$0.78 million (as of December 31, 2021: \$1.0 million), representing the cost of buildings of the E*Trade real estate (odd 02, odd 03 and odd 04) and the cost of buildings of the E*Trade real estate (2/Floor 11/F) in the office portfolio. See also "Investment Properties" section of the financial statements for more information regarding the investment properties and the office portfolio.

Investment properties	Cost of buildings of the E*Trade real estate (odd 02, odd 03 and odd 04)
Accumulated depreciation	Solaris, E*Trade real estate, and Solaris, E*Trade real estate
Net book value	75%
Goodwill (App. o.) (\$.M.)	1, 5 .41
Intangible assets (App. o.) (\$.M.)	

Management Discussion and Analysis

Accounts Payables

As of December 31, 2020, accounts payable decreased to B6.6¥ million (as of December 31, 2019: B75.6¥ million).

Contract Liability

As of December 31, 2020, contract liability decreased to B130¥ million (as of December 31, 2019: B8.6¥ million).

Other Payables

As of December 31, 2020, other payables decreased to B76.6¥ million (as of December 31, 2019: B133.3¥ million).

Financial Risk Management

The management has formulated and implemented effective control measures for the identification, measurement, monitoring and control of financial risks.

	For the year ended December 31,	
	2020 (RMB'000)	2019 (¥10,000)
Net cash generated from operating activities	199,656	111,800
Net cash used in investing activities	(186,320)	(10,531)
Net cash generated from financing activities	22,052	7,762
Net change/(decrease) in cash and cash equivalents	35,141	(22,115)

Net Cash Generated from Operating Activities

In the reporting period, net cash generated from operating activities amounted to B199.7¥ million, primarily consisting of the profit of B50¥ million, adjustment of B31.1¥ million for the impact of the new accounting standards, and adjustment of B123.8¥ million for the impact of the change in the accounting policy of the disposal of the subsidiary. Net cash generated from operating activities of B44.5¥ million, net cash outflow of B21.3¥ million and balance of

Net Cash Used in Investing Activities

In the reporting period, net cash used in investing activities amounted to B186.3¥ million, primarily due to the investment of B1880¥ million for the purchase of property, plant and equipment, (¥10,000,100) -1.556¥ million for the purchase of



Management Discussion and Analysis

Net Cash Generated from Financing Activities

The net cash generated from financing activities was B22.1 million.

Significant Investment, Acquisition and Disposal

The company did not have any significant investment, acquisition or disposal.

Shareholders

Bank Borrowings

As of December 31, 2022, the balance of bank borrowings of the company was B426.5 million (as of December 31, 2021: B300 million), primarily consisting of borrowings of B400 million and newly created borrowings of B26.5 million from the company.

Contingent Liability

As of December 31, 2022, the company has no contingent liability on the balance sheet and no related party relationship of operation of the company.

Asset Pledge

The company has no asset pledge from the company.

Lease Liabilities

The lease liability of the company is related to the operation of the company. As of December 31, 2022, the present value of the lease liability is B32.5 million, and the carrying amount is B18.8 million.

Financial Instruments

The financial instruments of the company include accounts receivable, other receivables, other payable, cash and cash equivalents, bank borrowings, accounts payable and other payable. The company does not have any derivatives or other financial instruments that are effective in hedging the company's risk.

Exposure to Fluctuation in Exchange Rates

The company's revenue is mainly derived from domestic, and the company's official currency is the RMB. The company's revenue is mainly derived from domestic, and the company's official currency is the RMB.

Management Discussion and Analysis

As of ended 31, 2020, the company's net fixed assets increased to Rs. 1,00,00,00,000 from Rs. 90,00,00,000 in the previous period. The increase in net fixed assets is due to the purchase of new fixed assets, including land, buildings, furniture, and other fixed assets. The increase in net fixed assets is also due to the depreciation of fixed assets.

Gearing Ratio

As of ended 31, 2020, the company's gearing ratio (total liabilities divided by total assets) has increased to 41.6% (as of ended 31, 2019: 40.4%), which is due to the increase of bank borrowings.

Employees and Remuneration Policy

As of ended 31, 2020, the company has a total of 3,338 full-time employees (as of ended 31, 2019: 2,845 full-time employees). The company's remuneration policy is based on the performance of the employees and the company's financial results. The remuneration policy is also based on the industry practice and the company's financial results. The remuneration policy is also based on the company's financial results and the industry practice. The remuneration policy is also based on the company's financial results and the industry practice.

The company has a total of 18 directors (as of ended 31, 2020) and 17 independent directors (as of ended 31, 2020). The company's remuneration policy is based on the performance of the directors and the company's financial results. The remuneration policy is also based on the industry practice and the company's financial results. The remuneration policy is also based on the company's financial results and the industry practice. The remuneration policy is also based on the company's financial results and the industry practice.

As of ended 31, 2020, the company has a total of 17 directors (as of ended 31, 2020) and 8 independent directors (as of ended 31, 2020). The company's remuneration policy is based on the performance of the directors and the company's financial results. The remuneration policy is also based on the industry practice and the company's financial results. The remuneration policy is also based on the company's financial results and the industry practice. The remuneration policy is also based on the company's financial results and the industry practice.

As of ended 31, 2020, the company has a total of 15 directors (as of ended 31, 2020) and 10 independent directors (as of ended 31, 2020). The company's remuneration policy is based on the performance of the directors and the company's financial results. The remuneration policy is also based on the industry practice and the company's financial results. The remuneration policy is also based on the company's financial results and the industry practice. The remuneration policy is also based on the company's financial results and the industry practice.

Report of the Board

The Board has prepared this report in accordance with the requirements of the Corporate Law and the regulations of the SEC, as of December 31, 2020.

Corporate Activities

The corporate activities of the company were carried out in accordance with the strategic plan approved by the Board of Directors of the company for the year 2020. The company has continued to operate in a normal manner, maintaining its operations in accordance with the requirements of the SEC and the regulations of the SEC.

The Board of Directors has approved the financial statements of the company for the year 2020, which are in accordance with the requirements of the SEC and the regulations of the SEC. The Board of Directors has also approved the annual report of the company for the year 2020, which is in accordance with the requirements of the SEC and the regulations of the SEC.

Board of Directors

The Board of Directors of the company is composed of five members, who are elected by the shareholders of the company. The Board of Directors is responsible for the management and administration of the company, and for the approval of the financial statements and the annual report of the company.

Financial Information

The company has reported a net loss of \$1,000,000 for the year 2020, which is due to the impact of the COVID-19 pandemic on the company's operations. The company's financial statements for the year 2020 are in accordance with the requirements of the SEC and the regulations of the SEC.

Dividends

The Board of Directors has approved the payment of dividends to the shareholders of the company for the year 2020. The dividends are in accordance with the requirements of the SEC and the regulations of the SEC.

Environmental and Social

The company is committed to environmental and social responsibility, and has implemented various measures to reduce its carbon footprint and improve its social performance. The company's environmental and social performance is in accordance with the requirements of the SEC and the regulations of the SEC.

Report of the Board

Compliance in the Regulatory Environment

The Group continues to be in compliance with applicable laws, regulations, and standards, including the SF, applicable codes of practice, and other regulatory requirements. It has achieved significant progress in the regulatory environment. Since the beginning, the compliance officer has been the executor of the Board of Directors.

Under the significant progress of the operation of the Group's business, the Group has implemented the Law of the People's Republic of China on Mental Health (《中華人民共和國精神衛生法》), the Law of the People's Republic of China on Basic Medical (《中華人民共和國基本醫療衛生與健康促進法》) (effective from 1, 2020), the Regulation on the Management of Medical Institutions (《醫療機構管理條例》) and the Implementation Rules of the Regulation on the Management of Medical Institutions (《醫療機構管理條例實施細則》).

The operation of the Group has completed in various areas of the regulatory environment. The Group's performance is satisfactory.

The Group has been able to identify and be transparent to the applicable laws, regulations, and standards. The Group has also been able to identify and be transparent to the applicable laws, regulations, and standards. The Group has also been able to identify and be transparent to the applicable laws, regulations, and standards.

The Group has identified the compliance in the regulatory environment. The Group has also been able to identify and be transparent to the applicable laws, regulations, and standards.

Review of Financial Position

For the year ended 31, 2020, the Group's operating performance is as follows.

Revenue of the Group

The Group's revenue for the year ended 31, 2020 is RMB 1,015.7 million. The Group's revenue for the year ended 31, 2019 is RMB 1,015.7 million. The Group's revenue for the year ended 31, 2018 is RMB 1,015.7 million. The Group's revenue for the year ended 31, 2017 is RMB 1,015.7 million. The Group's revenue for the year ended 31, 2016 is RMB 1,015.7 million. The Group's revenue for the year ended 31, 2015 is RMB 1,015.7 million.

Report of the Board

Introduction

The Board of Directors reports on the performance of the company for the year ended December 31, 2019.

Execution of Business

In accordance with the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》) and its implementation regulations which came into effect on January 1, 2008, the corporate income tax rate of the enterprise income tax is reduced to 25% from 33% of the tax base before the reduction. For the enterprise income tax, the enterprise income tax is calculated on the taxable income of the enterprise, including income from various sources, such as dividends, interest income, and income from the sale of property, and is reduced by 25% from the taxable income. Therefore, the enterprise income tax is calculated on the taxable income of the enterprise. The corporate income tax is calculated on the taxable income of the enterprise, including income from various sources, such as dividends, interest income, and income from the sale of property, and is reduced by 25% from the taxable income. Therefore, the enterprise income tax is calculated on the taxable income of the enterprise.

The enterprise income tax rate of 25% is applied to the taxable income of the enterprise. For the enterprise income tax, the enterprise income tax is calculated on the taxable income of the enterprise, including income from various sources, such as dividends, interest income, and income from the sale of property, and is reduced by 25% from the taxable income. Therefore, the enterprise income tax is calculated on the taxable income of the enterprise.

Report of the Board

State capital

... of

...

... of

...

... of

Report of the Board

Executive Director

For the year ended 31, 12, 2023, the report of the Executive Director is as follows:

Environmental & Social

For the year ended 31, 12, 2023, the Environmental & Social Committee has been established to monitor and report on the company's progress in achieving its environmental and social objectives.

Materiality

For the year ended 31, 12, 2023, the materiality assessment has been conducted to identify the environmental and social issues that are most significant to the company and its stakeholders. The assessment has identified 18.5% of the issues as material.

Sustainability

The company's sustainability strategy for the year ended 31, 12, 2023 is to focus on the following areas: Environmental, Social, and Governance. The company has set targets for each of these areas and is committed to reporting on its progress.

Disclosure

The company's sustainability report is available on the company's website at the following link: [www.abc.com/sustainability](#)

Executive Directors

- Mr. A. B. C. (Chairman)
- Mr. A. B. C. (Director)
- Mr. A. B. C. (Director)

Report of the Board

Speical

The Special Committee report on the performance of the Board:

1. Sri Raju (Chairman)
2. Anand
3. E. Iyer
4. Anand
5. E. Iyer

Board's Review and Analysis of the Performance of the Board for the year ended 31, 2020, and the Report of the Board on the Performance of the Board

The Board's Review and Analysis of the Performance of the Board for the year ended 31, 2020, and the Report of the Board on the Performance of the Board is a report.

Director's Special Committee, Annual Report on the Performance of the Board

The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020. The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020.

Director's Special Committee, Annual Report on the Performance of the Board

The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020. The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020.

Director's Special Committee

The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020. The Director's Special Committee, Annual Report on the Performance of the Board, is a report on the performance of the Board for the year ended 31, 2020.



Report of the Board

ο-competition A

The results of the competition A are as follows: ...

Report of the Board

Disclosure of Subsidiary Shareholding

As at December 31, 2020, according to the relevant provisions of the Company Law of the PRC and Article 336 of the SFOP, the Company is required to disclose the shareholding information of its directors, supervisors and senior management (collectively referred to as "Directors, Supervisors and Senior Management") and the shareholding information of the Company's subsidiaries. The Company is required to disclose the shareholding information of its subsidiaries in accordance with Article 3 of the SFOP, to be disclosed in the annual report of the Company.

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Share Capital ⁽¹⁾
廣州德福股權投資基金合夥企業 (有限合夥) (DeFu Fund) (廣州德福股權投資基金合夥企業 (有限合夥) (「德福基金」))	普通股	beneficial owner	15,384,541 (1)	27.84%	2.62%

Report of the Board

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Share Capital ⁽¹⁾
සමාගම	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය අයිතිකරු	1,345,722(L)	6.6%	1.0%
විදේශීය	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	1,454,000 (L)	7.52%	1.5%
විදේශීය	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	2,18,400 (L)	11.12%	2.88%
විදේශීය	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	1,27,400 (L)	6.62%	1.72%
විදේශීය	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	2,118,888(L)	10.95%	2.84%
විදේශීය	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	10,500(L)	0.0544%	0.141%
BS සමාගම	(A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලය	විදේශීය	4,35,6(L)	0.86%	5.41%

සටහන:

(1) විෂය විෂය

(1) විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීම 55,20,000 ජාතික ආර්ථික විද්‍යා විද්‍යාලයේ 1,30,800 (A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලයේ 74,60,800 (A) ශ්‍රී ලංකා ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීම 31,200.

(2) විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්.

(3) විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 52.45% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 52.45% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 52.45% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 52.45% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 52.45% ක්.

(4) විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්, විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්.

(5) විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්.

විදේශීය ආර්ථික විද්‍යා විද්‍යාලයේ මුළු බැඳීමේ 5% ක්.

Report of the Board

- (7) 上海盛歌投資管理有限公司(Shanghai Shengge Investment Management Co., Ltd.) is the representative of 上海盛歌投資管理合夥企業(有限合夥)(Shanghai Shengge Investment Management Partnership (Limited Partnership)) and 上海檀英投資合夥企業(有限合夥)(Shanghai Tanying Investment Partnership (Limited Partnership)), effective by law of the SF, 上海乾剛投資管理合夥企業(有限合夥)(Shanghai Qiangang Investment Management Partnership (Limited Partnership)) is the representative of 上海乾剛投資管理合夥企業(有限合夥)(Shanghai Qiangang Investment Management Partnership (Limited Partnership)) and 上海檀英投資合夥企業(有限合夥)(Shanghai Tanying Investment Partnership (Limited Partnership)) of the PRC.
- (8) 青島金石灝納投資有限公司(Qingdao Jinchishuonai Investment Co., Ltd.) is the representative of 金石投資有限公司(Jinshi Investment Co., Ltd.) effective by law of the PRC, 金石投資有限公司(Jinshi Investment Co., Ltd.) is the representative of 青島金石灝納投資有限公司(Qingdao Jinchishuonai Investment Co., Ltd.) of the PRC by law of the SF.

Shareholders above, as recorded by 31, 2020, are the only effective directors, officers and employees of the Company (including directors, as per the office of the PRC) and, as recorded by the company's annual general meeting of shareholders of the Company, are the only shareholders of the Company who are the effective directors, officers and employees of the Company as recorded by the company's annual general meeting of shareholders of the SF, as recorded by the company's annual general meeting of shareholders of the Company as per Section 336 of the SF.

Director's Special Information on Anti-Corruption and Bribery

Shareholder Environmental Science and Technology Development Center and the company's office are located in Beijing, the PRC, and the company's office is located in Beijing, the PRC. The company's office is located in Beijing, the PRC, and the company's office is located in Beijing, the PRC. The company's office is located in Beijing, the PRC, and the company's office is located in Beijing, the PRC.

Director's Declaration

The Board confirms that none of the directors, officers or employees of the Company has been involved in any corrupt or bribery practices in the course of the company's business activities. The Board confirms that none of the directors, officers or employees of the Company has been involved in any corrupt or bribery practices in the course of the company's business activities.

Report of the Board

Income, Sale of and Purchase of Listed Securities

None of the proposed transactions described above is expected to be a significant portion of the total assets or liabilities of the Company or effective, within the reporting period, the total reported amount of 82,000 (Sale of the (Total of Stock Exchange, including the total consideration (excluding expense) of (\$15,888,900) value of the reported amount of (:

Repurchase period	Total number of H Shares repurchased <i>(Share)</i>	Price paid per share		Total consideration <i>((\$))</i>
		Highest <i>((\$))</i>	Lowest <i>((\$))</i>	
Jan 2020	35000	17.0	17.0	624,000
Apr 2020	715,000	18.56	17.0	12,913,500
Jun 2020	8,400	16.00	15.0	148,500
Nov 2020	10,000	15.0	14.0	2,122,700
	82,000			15,888,900

The above reported (Sale of shares) of 13,000.

Sale and purchase of, within the reporting period, the value of the listed securities, not of the total assets or liabilities of the Company.

Use of Proceeds

The proceeds from the use of proceeds from the share capital and other public offerings of shares of the Company have been used in the following manner:

Bank Balance

As of the bank balance of the total of 31,000 shares of the Company and a share of 4.0% of (1) and (26) of the total of 31,000 shares of the Company.

Share of Assets

As of the total of 31,000 shares of the Company and a share of 4.0% of (1) and (26) of the total of 31,000 shares of the Company.

Report of the Board

Corporate Governance

The Board of Directors and the Company's activities in a corporation are conducted in accordance with the provisions of the Companies Act, 1956 and the Companies (Incorporation) Act, 2013 and the Companies Act, 2013 and the Companies (Incorporation) Act, 2013.

Statement of Financial Position

Based on the financial statements of the Company in the year ended 31st March 2021, the Board has approved the financial statements of the Company for the year ended 31st March 2021.

Right of Shareholders to Attend

For determining the entitlement to attend and vote at the AGM

The right of shareholders of the Company to be entitled to attend and vote at the AGM shall be effective from the date of the closure of the books of accounts of the Company for the year ended 31st March 2021, and shall be effective from the date of the closure of the books of accounts of the Company for the year ended 31st March 2021, and shall be effective from the date of the closure of the books of accounts of the Company for the year ended 31st March 2021.

Board of Directors and the Company's Activities

The Board of Directors and the Company's activities in a corporation are conducted in accordance with the provisions of the Companies Act, 1956 and the Companies (Incorporation) Act, 2013 and the Companies Act, 2013 and the Companies (Incorporation) Act, 2013.

Audit Committee

The Audit Committee of the Board of Directors of the Company has reviewed the financial statements of the Company for the year ended 31st March 2021, and has recommended the financial statements of the Company for the year ended 31st March 2021, and has recommended the financial statements of the Company for the year ended 31st March 2021.

Report of the Board

A 1.0

the financial statements for the year ended 31/12/2020 are based on the best estimate and on the opinion of the Board.

the Board also considers the financial statements to be fair.

For and on behalf of the Board

GUAN Weili



Director

April 16, 2021

Report of the Supervisory Committee

10.1.2. Scope of the Report:

10.1.2.1, the Supervisory Committee based on the audit of the financial statements of the Company, the Scope of the Report, the compliance with the laws and regulations, the audit of the Accounts, carried out in the period of the Report, the performance of the functions, and the effectiveness of the performance of the internal control, the effective of the internal control system of the Company, the impact of the internal control system on the performance of the Company.

10.1.2.2, the Report also, the Supervisory Committee based on the audit of the Company's operations, the performance of the Company, the compliance with the laws and regulations, the audit of the Accounts, carried out in the period of the Report, the performance of the functions, and the effectiveness of the performance of the internal control, the effective of the internal control system of the Company, the impact of the internal control system on the performance of the Company.

10.1.2.3, the Supervisory Committee based on the internal control system of the Company, the effectiveness of the internal control system, the compliance with the laws and regulations, the audit of the Accounts, carried out in the period of the Report, the performance of the functions, and the effectiveness of the performance of the internal control, the effective of the internal control system of the Company, the impact of the internal control system on the performance of the Company.

10.1.2.4, the Supervisory Committee based on the internal control system of the Company, the effectiveness of the internal control system, the compliance with the laws and regulations, the audit of the Accounts, carried out in the period of the Report, the performance of the functions, and the effectiveness of the performance of the internal control, the effective of the internal control system of the Company, the impact of the internal control system on the performance of the Company.

For and on behalf of the Supervisory Committee
SUN Fangjun
Chairman

April 16, 2021

Corporate Governance Report

El Consejo de Administración profesional de la compañía, en el ejercicio de sus funciones, ha elaborado el presente informe, el cual constituye un elemento esencial de la información financiera de la compañía.

Este informe tiene como propósito principal proporcionar información profesional de la compañía, en el ejercicio de sus funciones, al Consejo de Administración profesional de la compañía.

Corporate Governance Report

Accounting Standards

The Company has been applying the Accounting Standards for Business Enterprises issued on March 17, 2014, and the specific accounting policies of the Company are listed in Article 622 of the Charter of the Company (the Charter of the Company).

Accounting Policies

The financial statements are prepared in accordance with the Accounting Standards for Business Enterprises - Basic Standards, and the specific accounting policies are listed in Article 622 of the Charter of the Company of February 15, 2016 (the Charter of the Company) (please refer to the Accounting Standards for Business Enterprises or CAS).

The financial statements are prepared on a cost basis.

The Charter of the Company became effective on March 3, 2014. The specific financial statements of the financial statements have been prepared in accordance with the Charter of the Company.

Changes of Significant Accounting Policies

The change of significant accounting policies were only those of the Financial Statements. Significant change in accounting policies of financial reports.

Attendance of Board Members at the Annual Meeting

The Company has adopted the practice of online Board Meeting for the year 2016. The annual general meeting was held on March 20, 2016 in accordance with Article A.1.1 of the Charter of the Company. The Board Members participated in the annual general meeting in accordance with Article A.1.3 of the Charter of the Company. The attendance of the Board Members is as follows:

Corporate Governance Report

The report details the Board's activities and the effectiveness of the internal control system. The Board's activities are as follows:

Name of Directors	Number of Board meetings convened/attended
Executive Directors	
Mr. A. J. ()	0 / 0
Mr. A. J. ()	0 / 0
Mr. A. J. ()	0 / 0
Non-executive Directors	
Mr. A. J. ()	0 / 0
Mr. A. J. ()	0 / 0
Independent Non-executive Directors	
Mr. A. J. () ()	5/5
Mr. A. J. () ()	5/5
Mr. A. J. () ()	5/5
Mr. A. J. () ()	5/4
Mr. A. J. () ()	5/5
Mr. A. J. () ()	5/5

All internal control systems are subject to regular internal and external audits before the Board. The Board has accepted the internal control system as being in good compliance of the relevant laws and regulations, professional standards, and the company's policies.

The Board has established a separate committee to monitor the internal control system. The committee is composed of independent non-executive directors. The committee is responsible for monitoring the internal control system and reporting to the Board. The Board has also established a separate committee to monitor the internal control system. The committee is composed of independent non-executive directors. The committee is responsible for monitoring the internal control system and reporting to the Board.

Corporate Governance Report

The report details the performance of the Board of Directors of the company...

Table with columns: Name of Directors, Number of general meetings convened/attended. Rows include Executive Directors, Non-executive Directors, and Independent Non-executive Directors.

Board Committee

The Board is responsible for committees, the Audit Committee, the Nomination Committee, the Remuneration Committee and the Stakeholder Committee...

Audit Committee

The company is responsible for the Audit Committee compliance in 2021 and 2022 of the Code of Ethics, and the quality of reference compliance...

Corporate Governance Report

A main theme of the report, the Anti-Corruption Policy of the Independent Electricity Regulator, is the role of the Board (Chairman of the Anti-Corruption Committee) and the Independent Electricity Regulator, in the Anti-Corruption Policy of the Independent Electricity Regulator, and the role of the Board and the Independent Electricity Regulator in the Anti-Corruption Policy of the Independent Electricity Regulator.

The details of the Independent Electricity Regulator's Anti-Corruption Policy are as follows:

Directors	Number of meetings convened/attended
Mr. J. J. (Chairman) (appointed 18/11/18)	3/3
Mr. J. J. (appointed 18/11/18)	3/3
Mr. A. A. (appointed 18/11/18)	3/3
Mr. A. A. (appointed 18/11/18)	3/3
Mr. J. J. (appointed 18/11/18)	3/3
Mr. J. J. (appointed 18/11/18)	3/3

Director's Policy

The Director's Policy is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Director's Policy and the Board, and the Independent Electricity Regulator's responsibilities. The Director's Policy is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Director's Policy and the Board, and the Independent Electricity Regulator's responsibilities. The Director's Policy is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Director's Policy and the Board, and the Independent Electricity Regulator's responsibilities.

According to the Director's Policy for the Independent Electricity Regulator, the Director's Policy is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Director's Policy and the Board, and the Independent Electricity Regulator's responsibilities. The Director's Policy is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Director's Policy and the Board, and the Independent Electricity Regulator's responsibilities.

In the Independent Electricity Regulator's report, the Independent Electricity Regulator's Policy, for the Independent Electricity Regulator, is a key element of the Independent Electricity Regulator's corporate governance framework. It sets out the responsibilities of the Independent Electricity Regulator's Policy and the Board, and the Independent Electricity Regulator's responsibilities.



E A S A , .
A A E

Corporate Governance Report

The Board of Directors is responsible for the overall performance of the company and for the implementation of the corporate governance framework. The Board has established the following committees:

Directors	Number of meetings convened/attended
Mr. A. J. (Chairman) (appointed 18, 2020)	0/0
Mr. B. K. (appointed 18, 2020)	0/0
Mr. C. L. (appointed 18, 2020)	0/0
Mr. D. M. (appointed 18, 2020)	1/1
Mr. E. N. (appointed 18, 2020)	1/1
Mr. F. O. (appointed 18, 2020)	1/1

The Board of Directors is responsible for the overall performance of the company and for the implementation of the corporate governance framework.

Corporate Governance Report

The effectiveness of the economic and social and environmental performance of the company is a key focus of the Board of Directors.

Directors	Number of meetings convened/attended
Mr. A. J. (Director)	1/1
Mr. B. K. (Director)	0/0
Mr. C. L. (Director)	0/0
Mr. D. M. (Director)	1/1
Mr. E. N. (Director)	1/1

Board Composition

The Board of Directors is responsible for the overall strategic direction of the company and for ensuring that the company's resources are used effectively to achieve its objectives. The Board is also responsible for monitoring and reviewing the company's performance and for ensuring that the company is managed in accordance with the highest standards of corporate governance. The Board is composed of five members, three of whom are independent non-executive directors. The Board also includes a Chairman and a Director of Finance. The Board's composition is designed to ensure that it has the necessary skills and experience to oversee the company's operations and to provide strategic guidance to the management.

The Current Composition of the Board

Age	Gender	Years of service as Director
31 - 40 years (3 people)	Female (37.5%)	1 - 5 years (4 people)
51 - 60 years (4 people)	Male (62.5%)	6 - 10 years (4 people)

Corporate Governance Functions

The Board is responsible for the following corporate governance functions:

- (a) to ensure the company complies with the relevant regulatory and legal requirements;
- (b) to ensure the company provides a safe and sound practice of corporate governance;
- (c) to ensure the company's policies and procedures are applied consistently and effectively;
- (d) to ensure the company's financial statements are prepared in accordance with the relevant accounting standards and practices;
- (e) to ensure the company provides a high level of transparency and accountability to its stakeholders.

Corporate Governance Report

In the report, the Board, as independent committee, performs the following corporate governance functions: (1) monitor the A's compliance with the law and regulations; (2) monitor the A's financial performance; (3) monitor the A's compliance with the Securities and Exchange Commission's rules; (4) monitor the A's compliance with the corporate governance and performance disclosure requirements; and (5) monitor the A's compliance with the law and regulations.

Director's and A's Responsibility for Environmental and Social Impact of the A's Business

The Director's and A's responsibility for environmental and social impact of the A's business is defined as the responsibility of the Director's and A's to identify, assess, and manage the environmental and social risks and opportunities of the A's business. The Director's and A's responsibility for environmental and social impact of the A's business is defined as the responsibility of the Director's and A's to identify, assess, and manage the environmental and social risks and opportunities of the A's business.

The Director's and A's responsibility for environmental and social impact of the A's business is defined as the responsibility of the Director's and A's to identify, assess, and manage the environmental and social risks and opportunities of the A's business.

The Director's and A's responsibility for environmental and social impact of the A's business is defined as the responsibility of the Director's and A's to identify, assess, and manage the environmental and social risks and opportunities of the A's business.

Director's and A's Responsibility for Environmental and Social Impact of the A's Business

The Board is responsible for the A's environmental and social performance. The Board is responsible for the A's environmental and social performance. The Board is responsible for the A's environmental and social performance. The Board is responsible for the A's environmental and social performance.

A's environmental and social performance is defined as the A's ability to identify, assess, and manage the environmental and social risks and opportunities of the A's business. The A's environmental and social performance is defined as the A's ability to identify, assess, and manage the environmental and social risks and opportunities of the A's business. The A's environmental and social performance is defined as the A's ability to identify, assess, and manage the environmental and social risks and opportunities of the A's business.

Corporate Governance Report

The Board has fully implemented the national and international standards of corporate governance, and the results of the implementation are in line with the requirements of the relevant laws and regulations and the expectations of the shareholders.

In order to protect the legitimate interests of the shareholders, the company has established a complete system of corporate governance, including the constitution, articles of association, internal rules of procedures, and the appointment and removal of directors, supervisors, and senior management. The Board has fully implemented the national and international standards of corporate governance, and the results of the implementation are in line with the requirements of the relevant laws and regulations and the expectations of the shareholders.

Senior Management's Remuneration

The remuneration of the senior management members of the company is determined according to the "Company's Senior Management Remuneration Policy", and the remuneration for the year ended December 31, 2023 is as follows:

Remuneration band (RMB)	Number of individuals
0 -50,000	4
50,000 -1,000,000	2

Airline's Remuneration

For the year ended December 31, 2023, the company's airline has fully implemented the national and international standards of corporate governance, and the results of the implementation are in line with the requirements of the relevant laws and regulations and the expectations of the shareholders.

Airline's remuneration	RMB 0.00
Total remuneration	RMB 24.00

Corporate Governance Report

Procedures for Directing Shareholders' Enquiries to the Board

Shareholders are advised to direct their enquiries to the Board via the following electronic address for:

Attention:

Mr. S. S. Wong
 Director, Finance
 Director, HR
 Tel:

Fax: (86) 577 8878, 117

Email: ir@etals.com.hk

Shareholders are advised to direct their enquiries to the Board via the following email address:

ir@etals.com.hk

or the appropriate Director, Finance and HR Director.

The proposed committee of directors of the Board of the Company has approved the proposal of the Board of the Company to amend the Articles of Association of the Company to comply with the requirements of the Securities and Futures Commission (SFC) under the Securities and Futures Ordinance (SFO) and the Listing Rules of the Stock Exchange of Hong Kong (SEHK). The proposed amendments to the Articles of Association of the Company are set out in the Appendix to the Circular Letter of the Board of the Company dated 17, 2022 (the "Circular Letter"). The proposed amendments to the Articles of Association of the Company have been approved by the Board of the Company on 22, 2022 and the amendments to the Articles of Association of the Company have become effective from 22, 2022, and it has been published in the Gazette of the Stock Exchange of Hong Kong. For details, please refer to the Circular Letter of the Board of the Company dated 17, 2022.

The proposed committee of directors of the Board of the Company has approved the proposal of the Board of the Company to amend the Articles of Association of the Company to comply with the requirements of the SFC under the SFO and the Listing Rules of the SEHK. The proposed amendments to the Articles of Association of the Company are set out in the Appendix to the Circular Letter of the Board of the Company dated 17, 2022. The Board of the Company has approved the proposed amendments to the Articles of Association of the Company on 22, 2022 and the amendments to the Articles of Association of the Company have become effective from 22, 2022, and it has been published in the Gazette of the Stock Exchange of Hong Kong. For details, please refer to the Circular Letter of the Board of the Company dated 17, 2022.

Corporate Governance Report

Introduction

The Board of Directors is pleased to present this report on the company's performance during the reporting period. The Board is committed to ensuring the company's long-term success and sustainable growth, while also maintaining high standards of corporate governance and ethical conduct. The Board's primary responsibility is to oversee the management of the company and to ensure that the company is managed in the best interests of all stakeholders. The Board has a diverse composition of members, including independent non-executive directors, who bring a wealth of experience and expertise to the company. The Board's activities during the reporting period are detailed in this report, including its meetings, decisions, and the actions taken to address the company's strategic objectives. The Board is also committed to transparency and accountability, and will continue to work closely with the management and stakeholders to ensure the company's success in the future.

The Board of Directors is pleased to present this report on the company's performance during the reporting period. (The following information is for information only):

- (1) **Chairman of the Board**;
- (2) **Independent Non-Executive Directors**;
- (3) **Members of the Board of Directors**, including the Chairman of the Board, the Independent Non-Executive Directors, the Executive Directors, and the Non-Executive Directors.

The Board of Directors is pleased to present this report on the company's performance during the reporting period. The Board of Directors is committed to ensuring the company's long-term success and sustainable growth, while also maintaining high standards of corporate governance and ethical conduct. The Board's primary responsibility is to oversee the management of the company and to ensure that the company is managed in the best interests of all stakeholders. The Board has a diverse composition of members, including independent non-executive directors, who bring a wealth of experience and expertise to the company. The Board's activities during the reporting period are detailed in this report, including its meetings, decisions, and the actions taken to address the company's strategic objectives. The Board is also committed to transparency and accountability, and will continue to work closely with the management and stakeholders to ensure the company's success in the future.

The Board of Directors is pleased to present this report on the company's performance during the reporting period. The Board of Directors is committed to ensuring the company's long-term success and sustainable growth, while also maintaining high standards of corporate governance and ethical conduct. The Board's primary responsibility is to oversee the management of the company and to ensure that the company is managed in the best interests of all stakeholders. The Board has a diverse composition of members, including independent non-executive directors, who bring a wealth of experience and expertise to the company. The Board's activities during the reporting period are detailed in this report, including its meetings, decisions, and the actions taken to address the company's strategic objectives. The Board is also committed to transparency and accountability, and will continue to work closely with the management and stakeholders to ensure the company's success in the future.

Directors, Supervisors and Senior Management

Mr. LIN Lijun (林利軍), age 48, is an independent director. He is responsible for supervising the company's business operations and financial activities. Since April 16, 2023, he has been a director of the company. He is also a director of the company's subsidiary, Yinko Investment Control Co., Ltd. (銀科投資控股有限公司), a company listed on the ASX stock exchange (ticker code: YINKO). Since April 16, 2023, he has been a director of the company's subsidiary, International Food Group Co., Ltd. (國際天食集團有限公司), a company listed on the ASX stock exchange (ticker code: 3666). He is also a director of the company's subsidiary, International Food Group Co., Ltd. Since April 16, 2023, he has been a director of the company's subsidiary, International Food Group Co., Ltd.

Directors, Supervisors and Senior Management

Director of Administration. Since April 14, he has been the chairman of the Board of Directors of the Academic Association of the Company. Since April 1, he has been the chairman of the Board of Directors of the Academic Association of the Company. Since September 14, he has been the chairman of the Board of Directors of the Academic Association. Since October 1, he has been the chairman of the Board of Directors of the Academic Association. In addition, he has been the chairman of the Board of Directors of the Academic Association. Since February 13, he has been the chairman of the Board of Directors of the Academic Association.

Ms. ZHONG Wentang (鐘文堂), age 32, has been the representative shareholder of the Company, since February 1, 2020, and has been the representative shareholder of the Company since February 16 to February 1, 2020. She has been the representative shareholder of the Company since February 12 to February 16, 2020. She has been the representative shareholder of the Company since February 1, 2020.

Mr. LIU Ning (劉寧), age 5, has been the chairman of the Board of Directors of the Company since April 4, 2020, and has been the chairman of the Board of Directors of the Company since February 18, 2020. He has been the chairman of the Board of Directors of the Company since February 18, 2020. He has been the chairman of the Board of Directors of the Company since February 1, 2020. He has been the chairman of the Board of Directors of the Company since April 11 to April 4, 2020. He has been the chairman of the Board of Directors of the Company since April 11, 2020. He has been the chairman of the Board of Directors of the Company since April 11, 2020.

Directors, Supervisors and Senior Management

SE A A E E

Mr. ZHOU Chaoyi (周朝毅), age 53, is an officer of a public company. He has been a director of the Company since February 2005 and has been an officer of a public company since he was appointed as an officer of the Company on September 14, 2004. He has also been a joint stock limited liability company director since February 5, 2004. He has been a vice president of the Wenzhou Heart Vascular Hospital (溫州心血管醫院) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Traditional Chinese Medicine Hospital (溫州市中醫院) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Qi Gong Therapy and Rehabilitation Center (溫州市氣功療養院) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (溫州市衛生局) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省衛生廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005.

Mr. YE Minjie (葉敏捷), age 47, is an officer of a public company. He has been a director of the Company since February 13, 2005 and has been an officer of a public company since he was appointed as an officer of the Company on September 14, 2004. He has also been a joint stock limited liability company director since February 4, 2005. He has been a vice president of the Wenzhou City Mental Hospital (溫州市精神病院) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (溫州市衛生局) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省衛生廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005.

Mr. XU Yi (徐誼), age 46, is an officer of a public company. He has been a director of the Company since February 20, 2005 and has been an officer of a public company since he was appointed as an officer of the Company on September 14, 2004. He has been a vice president of the Wenzhou City Health Bureau (溫州市衛生局) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省衛生廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005. He has been a vice president of the Wenzhou City Health Bureau (浙江省人力資源和社會保障廳) since he was appointed as a director of the Company in February 2005.

Directors, Supervisors and Senior Management

Mr. JIN Weiguang (金偉光), age 54, is an executive director. He is responsible for the overall operation and management of the company. He has worked in the pharmaceutical industry for over 15 years. He is currently the general manager of the company. He has also held various positions in the industry, including vice president of the company, director of the company, and vice president of the company. He has a bachelor's degree in medicine from the University of Medicine and Health Sciences. He has also held various positions in the industry, including vice president of the company, director of the company, and vice president of the company. He has a bachelor's degree in medicine from the University of Medicine and Health Sciences. He has also held various positions in the industry, including vice president of the company, director of the company, and vice president of the company. He has a bachelor's degree in medicine from the University of Medicine and Health Sciences.

Salary, incentive, remuneration, etc. are determined by the Board of Directors, Supervisors and Senior Management of the company.

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
Chairman	Mr. JIN Weiguang (金偉光)	Executive Director	From April 11, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From May 12, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From December 12, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From September 13, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From September 14, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From April 15, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From October 15, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From October 15, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From September 15, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From October 15, 2019 to present
	Mr. JIN Weiguang (金偉光)	Executive Director	From April 20, 2019 to present

Directors, Supervisors and Senior Management


Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From April 11, 2011 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From September 13, 2013 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From September 14, 2014 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From October 15, 2015 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From August 21, 2015 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From September 15, 2015 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From October 15, 2015 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From December 18, 2018 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From December 15, 2018 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From December 1, 2019 to present
	Mr. [Name] (Independent Non-Executive Director)	Special Director	From July 7, 2021 to present

Directors, Supervisors and Senior Management

Directors/Senior Management	Members of the Group	Positions Held at Members of the Group	Term of Office
Chairman	Mr. Wang Yong	Chairman	From 2016 to present
	Mr. Wang Yong (Independent Director), Mr. Wang Yong (Independent Director)	Special Director	From 2017 to present
Directors	Mr. Wang Yong (Independent Director)	Chairman	From 2016 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present
	Mr. Wang Yong (Independent Director)	Chairman	From 2017 to present

(A) Filed 018.2680 (The name of the company) 18.2680 (The name of the company)

Auditor's Report



PWC

永道

Auditor's Report

S a i (2 2 1) o . 1 0 0 8
(I a e 2 of 8)

e A i a e .

e a i a e a e o e a e . a , i o . p o f e i o a j * a e , e o f o i v i l c a c e i o . a i o f e
i i d a a e e i o f e c e e p e i o . e e a e e e a e e e i o e c o e s o f o a i o f e i i d a
a e e a a o e , a i o f o i o o p i o i e e e , a i e o o p o i e a e p a e o p i o i o e e a e .

e a i a e i e i e i e i o . a i a e . a i e a f o o :

- Assessment for goodwill impairment of healthcare service
- Assessment for the impairment of contractual rights to provide management service



Auditor's Report

S... i... (2021) ... 1008
(Page 3 of 8)

e A... (co... e...)

Key Audit Matter

How our audit addressed the Key Audit Matter

Assessment for goodwill impairment of healthcare service

efe... o... e... (18) ... of ... - e... ,
o... e... (18) ...) ... acco... e... e... e...



Auditor's Report

Standard (2021) of 1008
(Page 4 of 8)

Key Audit Matter

The audit identified a risk of material misstatement because of the significant impact of the COVID-19 pandemic on the company's operations. The risk is that the company's financial statements do not accurately reflect the impact of the pandemic on the company's operations.

How our audit addressed the Key Audit Matter

We conducted a detailed analysis of the company's operations and financial statements to assess the impact of the COVID-19 pandemic. We also performed a sensitivity analysis to assess the impact of the pandemic on the company's financial statements.

We also performed a detailed analysis of the company's operations and financial statements to assess the impact of the COVID-19 pandemic. We also performed a sensitivity analysis to assess the impact of the pandemic on the company's financial statements.

We also performed a detailed analysis of the company's operations and financial statements to assess the impact of the COVID-19 pandemic. We also performed a sensitivity analysis to assess the impact of the pandemic on the company's financial statements.

Based on the results of the above procedures, we found that the company's financial statements are not materially misstated. We also found that the company's operations are not materially impacted by the COVID-19 pandemic.

Assessment for the impairment of contractual rights to provide management service

Refer to paragraph 18 of the audit report, paragraph 28(a) of the audit report, and paragraph 4(13) of the audit report.

As at 31 December 2020, the company's operations are not materially impacted by the COVID-19 pandemic. The company's operations are not materially impacted by the COVID-19 pandemic. The company's operations are not materially impacted by the COVID-19 pandemic.

We observed that the company's operations are not materially impacted by the COVID-19 pandemic. We also observed that the company's operations are not materially impacted by the COVID-19 pandemic. We also observed that the company's operations are not materially impacted by the COVID-19 pandemic.

We also observed that the company's operations are not materially impacted by the COVID-19 pandemic. We also observed that the company's operations are not materially impacted by the COVID-19 pandemic. We also observed that the company's operations are not materially impacted by the COVID-19 pandemic.

Auditor's Report

Key Audit Matter

How our audit addressed the Key Audit Matter

Auditor's Report

Section 1008
(Page 6 of 8)

Verifying

the auditor's responsibility to the board of directors. The auditor's primary responsibility is to the board of directors. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements.

the auditor's responsibility to the board of directors. The auditor's primary responsibility is to the board of directors. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements.

The auditor's primary responsibility is to the board of directors. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements. The auditor's responsibility to the board of directors is to provide an opinion on the company's financial statements.

Auditor's Report

Standard 1008
(Page 8 of 8)

Audit opinion for the Audit of the Haidasaidan (company)

The opinion of the Audit Committee is that the financial statements prepared in accordance with the accounting standards, and the accounting information provided in the financial statements are reliable and free from material misstatements, and the applicable laws and regulations are followed.

For the reasons mentioned in the Audit Committee, the financial statements are free from material misstatements, and the financial statements are reliable and free from material misstatements. The financial statements are reliable and free from material misstatements, and the financial statements are reliable and free from material misstatements. The financial statements are reliable and free from material misstatements, and the financial statements are reliable and free from material misstatements.

The representative of the company is	Signed: [Signature]	Chen Zhiming (Director of Finance)
Signed: [Signature] 26 Dec 2021	Signed: [Signature]	Chen Yi

Consolidated Balance Sheet

As at 31 December 2020
 (As approved by the Board of Directors)

ASSETS	Code	31 December 2020	31 December 2019
Current assets			
Trade receivables	4(1)	206,499,564	170,000,550
Prepaid expenses		-	3,000,000
Accounts receivable	4(2)	321,407,965	30,500,612
Other receivables	4(3)	63,435,813	63,317,366
Advance on purchase	4(4)	11,927,882	5,360,000
Inventory	4(5)	37,508,471	23,568,236
Other portion of other-current assets	4(6)	-	12,688,004
Total current assets		640,779,695	621,418,768
Non-current assets			
Long-term investments	4(7)	93,726,511	89,431,133
Other portion of other non-current assets	4(8)	57,404,918	51,281,866
Investment properties	4(9)	107,804,936	10,856,000
Receivables	4(10)	533,743,384	552,400,802
Other portion of other non-current assets	4(11)	134,941,286	72,100,600
Intangible assets	4(12)	227,568,279	235,312,144
Other non-current assets	4(13)	162,536,728	10,881,128
Goodwill	4(14)	71,605,598	54,346,633
Long-term prepaid expenses	4(15)	153,550,840	151,833,314
Deferred tax assets	4(16)	46,576,821	46,275,000
Other portion of other non-current assets	4(17)	18,708,451	1,716,666
Total non-current assets		1,608,167,752	1,458,800,367
TOTAL ASSETS		2,248,947,447	2,117,351,855

Consolidated Balance Sheet

As at 31 December 2020
(Approved by the Board of Directors)

LIABILITIES AND SHAREHOLDERS' EQUITY	in million TL	31 December 2020	31 December 2019
Current liabilities			
Short-term borrowings payable	4(1)	312,500,000	20,000,000
Trade payables		36,080	
Accounts payable	4(2)	69,573,927	75,554,000
Other liabilities	4(21)	12,965,170	8,562,126
Employee benefits payable	4(22)	42,785,133	30,632,777
Other payables	4(23)	49,046,555	33,400,000
Other payables	4(24)	76,603,400	133,348,712
Provision of other-current liabilities	4(25)	35,540,617	7,741,222
Total current liabilities			

Total of non-current liabilities 8,680,000

Company Balance Sheet

As at 31 December 2020

(Approved by the Board of Directors on 15 January 2021)

ASSETS	Note	31 December 2020	31 December 2019
Current assets			
Trade receivables		118,136,805	101,280,806
Prepaid expenses		-	3,000,000
Accounts receivable	16(1)	78,544,241	79,205,315
Accounts payable	16(2)	1,931,488	78,172
Other		521,673,904	564,146,003
Other		10,374,364	8,012,112
Other		-	12,688,004
Total current assets		730,660,802	816,728,812
Non-current assets			
Other	4(8)	57,404,918	51,281,866
Other	16(3)	453,843,360	337,636,655
Other	16(4)	299,191,394	301,282,258
Other		3,144,167	113,500
Other		-	80,000
Other	16(5)	22,383,643	22,555,734
Other		17,188,510	18,875,432
Other		556,900	78,000
Other		7,655,891	8,347,166
Total non-current assets		861,368,783	748,281,400
TOTAL ASSETS		1,592,029,585	1,565,010,212

Company Balance Sheet

As at 31 December 2020
(Amounts in US\$ million)

LIABILITIES AND SHAREHOLDERS' EQUITY	2020	31 December 2020	31 December 2019
Current liabilities			
Short-term borrowings		310,000,000	20,000,000
Accounts payable		32,572,146	38,432,788
Other liabilities		3,480,240	2,068,872
Employee benefits payable		15,629,766	15,571,352
Other payable		8,267,931	5,76,133
Other payable		25,329,546	64,81,712
Other portion of other-current liabilities		-	52,688,044
Total current liabilities		395,279,629	40,367,571
Non-current liabilities			
Long-term borrowings		38,000,000	-
Lease liability		-	766,152
Provision		-	200,000
Deferred income		9,645,475	9,942,267
Deferred liability		1,607,649	76,887
Total non-current liabilities		49,253,124	12,721,313
Total liabilities		444,532,753	443,151,884
Shareholders' equity			
Share capital	4(0)	74,600,300	75,000,000
Reserves	16(7)	828,516,606	834,663,552
Less: Reserves	9(b)(1)	(23,311,144)	(21,721,144)
Share premium	4(32)	36,593,229	33,183,321
Other equity	16(8)	231,097,841	20,462,672
Total shareholders' equity		1,147,496,832	1,120,444,408
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		1,592,029,585	1,565,254,292

The accompanying notes form an integral part of these financial statements.

Prepared by:
Auditor

Independent member of accountants:
Auditor

Chief financial officer:
CFO

Consolidated Income Statement

For the year ended 31 December 2020
(All amounts in B. M. T. e. i. e. e.)

Item	2020	2019
1. Revenue	1,031,283,760	80,617,8
Less: cost of sale	(728,701,852)	(656,184,564)
depreciation	(5,413,866)	(5,226,866)
Share distribution expense	(8,072,345)	(7,77,677)
depreciation on fixed assets	(125,062,445)	(123,338,42)
depreciation on other assets	(20,972,502)	(18,07)
Provision for	(22,821,708)	(23,488,174)
Provision for	(26,557,119)	(26,563,06)
Provision for	4,677,222	4,477,337
Provision for	9,264,825	1,32,548
Provision for (other) income	(7,665,311)	24,336,266
Provision for Share of profit of associate	(7,727,019)	(3,03,144)
Provision for other financial	6,599,223	1,17,462
Provision for	(23,125,756)	(2,256,324)
Provision for	(8,011,603)	
Provision for	596,700	
2. Operating profit	97,897,120	45,847,348
Provision for other income	909,040	3,388,527
Provision for	(10,901,945)	(1,713,68)
3. Total profit	87,904,215	55,522,07
Provision for	(28,948,671)	(17,518)

Consolidated Income Statement

For the period of 31 December 2021
(As reported by the Board of Directors)

Item	2021	2020
4. Net profit	58,955,544	38,227,618
Profit before tax		
Profit before tax from operations	58,955,544	38,227,618
Profit before tax from other operations	-	-
Profit before tax		
Profit before tax from operations		
Profit before tax from other operations		
Profit before tax	70,000,134	57,28,334
Income tax expense	(11,044,590)	(1,061,776)

Company Income Statement

For the year ended 31 December 2020
(All amounts in B. K. Baht unless otherwise stated)

Item	2020	2019
1. Revenue	417,163,187	384,066,640
Less: Cost of sales	(273,011,115)	(273,017,701)
- Distribution	(3,021,822)	(2,916,613)
- Selling and administrative	(2,321,386)	(2,488,613)
- Depreciation and amortization	(54,661,422)	(62,554,461)
- Other	(15,876,537)	(3,574,462)
- Provision for doubtful debts	(2,113,011)	(7,740,711)
- Provision for contingencies	(16,578,015)	(10,570,761)
- Provision for income tax	(13,418,117)	(2,427,741)
After: Income tax	4,253,758	7,463,671
- Provision for (income) tax	(8,163,228)	755,472
- Provision for Share of profit of associate	(8,158,636)	(632,381)
- Profit on disposal of subsidiary	6,123,114	17,546
- Other	(7,433,110)	(14,531,228)
- Other	(10,847,018)	-
2. Operating profit	47,970,115	26,207,811
After: Other operating income	7,824	27,684
Less: Other operating expense	(40,625,181)	(11,483,854)
3. Total profit	44,733,411	42,511,641
Less: Income tax expense	(10,643,334)	(10,515,824)
4. Net profit	34,090,077	32,000,866
- Profit before income tax	34,090,077	32,000,866
- Profit after income tax	34,090,077	32,000,866
5. Total comprehensive income	34,090,077	32,000,866

Accounting profit is based on the application of the accounting standards.

See page 82 for:
Additional

Information on the accounting:
Additional

Details of accounting:
Additional

Consolidated Cash Flow Statement

For the year ended 31 December 2020
(As approved by the Board of Directors)

Item	2020	2019
------	------	------

Consolidated Cash Flow Statement

For the year ended 31 December 2020
(Amount in million Singapore dollars)

Item	2020	2019
3. Cash flows from financing activities		
Proceeds from capital contributions	23,361,500	12,345,000
Net change in cash and cash equivalents from financing activities	21,771,500	12,345,000
Proceeds from borrowings	406,492,970	20,000,000
Proceeds from other financing activities	-	11,000,000
Sub-total of cash inflows	429,854,470	24,345,000
Repayment of borrowings	(290,000,000)	(18,000,000)
Payments for acquisition of investments in subsidiaries	(17,109,612)	(10,361,800)
Payments from other financing activities	(100,692,478)	(72,072,420)
Sub-total of cash outflows	(407,802,090)	(286,543,431)
Net cash flows from financing activities	22,052,380	7,761,569
4. Effect of foreign exchange rate changes on cash and cash equivalents	(248,021)	(635,428)
5. Net increase/(decrease) in cash and cash equivalents	35,140,715	(22,114,744)
At the beginning of the year	164,951,950	187,066,694
6. Cash and cash equivalents at the end of the year	200,092,665	164,951,950

The accounting policy for the cash and cash equivalents is set out in the notes to the financial statements.

Legal representative:
Audi

Independent member of accountants:
A (P)te

Legal representative:
Audi

Company Cash Flow Statement

For the year ended 31 December 2020
(Amount in RM Billion (in million))

Item	2020	2019
1. Cash flows from operating activities		
Receipts from sale of goods and services	430,696,545	388,82,58
Receipts from operating activities	64,986,508	11,0,8
Sub-total of cash inflows	495,683,053	40,72,488
Payments for goods and services	(161,484,999)	(125,886,385)
Payments for acquisition of property	(135,403,738)	(124,57,846)
Interest on loans	(9,282,581)	(18,265,441)
Payments from operating activities	(30,870,989)	(56,68,06)
Sub-total of cash outflows	(337,042,307)	(325,43,078)
Net cash flows used in operating activities	158,640,746	75,353,40
2. Cash flows from investing activities		
Receipts from disposal of assets	49,000,000	447,5
Receipts from sale of assets	96,370	1,526,05
Receipts from operating activities	3,750,000	
Sub-total of cash inflows	52,846,370	1,73,00
Payments on acquisition of subsidiaries	(38,292,840)	(220,7,144)
Payments on acquisition of assets	(158,247,608)	(20,70,000)
Payments from operating activities	(5,370,000)	
Sub-total of cash outflows	(201,910,448)	(232,757,144)
Net cash flows used in investing activities	(149,064,078)	(20,783,544)

Company Cash Flow Statement

For the year ended 31 December 2020
(All amounts in BHK million unless otherwise stated)

Item	2020	2019
3. Cash flows from financing activities		
Proceeds from capital contribution	1,590,000	
Proceeds from borrowings	348,000,000	20,000,000
Proceeds from other financing activities	-	0,000,000
Sub-total of cash inflows	349,590,000	20,000,000
Repayment of borrowings	(300,000,000)	(14,000,000)
Payment for acquisition of subsidiaries		
Interest expense	(16,486,881)	(18,658,586)
Payment from other financing activities	(14,507,167)	(265,816)
Sub-total of cash outflows	(330,994,048)	(163,562,002)
Net cash flows from financing activities	18,595,952	56,437,998
4. Effect of foreign exchange rate changes on cash	(248,021)	(635,428)
5. Net increase/(decrease) in cash and cash equivalents	27,924,599	(5,627,644)
At the beginning of the year	90,212,206	14,800,100
6. Cash and cash equivalents at the end of the year	118,136,805	9,172,456

The accounting policy for the cash and cash equivalents is as follows:

Deposits held in banks and other financial institutions are classified as cash and cash equivalents if they are available for use within 12 months of the reporting date.

Consolidated Statement of Changes in Shareholders' Equity

For the year ended 31 December 2020
(All amounts in B Maldivian Rufiyaa)

	Equity attributable to shareholders of the parent company							Total shareholders' equity
	Note	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Non-controlling interests	
Balance at 1 January 2020		75,500,000	824,715,445	(21,721,144)	33,189,321	252,800,715	97,024,925	1,261,509,262
Movements for the year ended								
31 December 2020								
Ordinary dividend		-	-	-	-	70,000,134	(11,044,590)	58,955,544
Share contribution		-	-	-	-	-	-	-
Share contribution		-	1,590,000	(1,590,000)	-	-	21,771,500	21,771,500
Share-based payment		-	5,887,603	-	-	-	-	5,887,603
Share contribution	4(31)	-	(13,813,742)	-	-	-	(19,879,038)	(33,692,780)
Share contribution	4(31)	(899,700)	(13,624,556)	-	-	-	-	(14,524,256)
Share contribution	4(31)	-	(188,221)	-	-	-	-	(188,221)
Share contribution		-	-	-	-	-	-	-
Share contribution	5(1)	-	-	-	-	-	15,905,745	15,905,745
Share contribution		-	-	-	3,403,908	(3,403,908)	-	-
Share contribution	4(33)	-	-	-	-	-	(1,200,000)	(1,200,000)
Balance at 31 December 2020		74,600,300	804,566,529	(23,311,144)	36,593,229	319,396,941	102,578,542	1,314,424,397

The accompanying notes form an integral part of these financial statements.

Equity and liabilities of equity companies

Account	Share capital		Reserves		Share premium	Retained earnings	Total equity
	Share capital	Reserves	Reserves	Share premium			
Balance at 1 January 2019	75,000,000	827,373,886	(213,300,000)	4,810,340	20,044,008	84,277,828	1,052,733,562
Movements for the year ended 31 December 2019							
Share-based payments					57,283,340	(1,061,776)	38,227,618
Share-based payments							
Share-based payments						12,343,000	12,343,000
Share-based payments		5,005,526					5,005,526
Share-based payments						(4,606,611)	(8,600,000)
Share-based payments		(188,856)	188,856				
Share-based payments		(4,057,222)				(2,150,860)	(6,857,082)
Share-based payments						26,585,500	26,585,500
Share-based payments					3,082,287	(3,082,287)	
Share-based payments	4(33)					(11,323,000)	(11,323,000)
Balance at 31 December 2019	75,000,000	824,715,445	(21,721,144)	33,183,321	252,007,715	7,702,405	1,061,098,262

Accounting for the year ended 31 December 2019

Legal representative:
Audi

Independent member of accounting firm:
Audi

Member of accounting firm:
Audi

Company Statement of Changes in Shareholders' Equity

For the year ended 31 December 2020
(Amounts in B US Dollars in millions)

	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Total shareholders' equity
Balance at 1 January 2020	75,500,000	834,663,559	(21,721,144)			

Company Statement of Changes in Shareholders' Equity

For the year ended 31 December 2019
(All amounts in B Maldivian Rufiyaa)

	Share Capital	Reserves	Retained Earnings	Share Premium	Other Reserves	Total
Balance at 1 January 2019	75,000,000	828,318,88	(21,000,000)	4,810,34	182,130,3	10,541,016
Movements for the year ended 31 December 2019						
Profit for the year					30,82,866	30,82,866
Share-based payments		(188,856)	188,856			
Share-based payments		5,0,526				5,0,526
Appropriation for reserves				3,08,287	(3,08,287)	
Transfer of reserves					(11,32,000)	(11,32,000)
Balance at 31 December 2019	75,000,000	834,663,55	(21,721,144)	33,18,321	20,462,672	1,120,4,408

The accounts are prepared on the basis of the accounting records.

Prepared by: Approved by: Director of Accounts:
 A. D. I. A. D. I. A. D. I.

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise stated)

1. General information

The Group is a special non-profit cooperative enterprise established by the Wuzhou Municipal Kangning Psychiatric Hospital (溫州市康寧精神康復醫院) on 7 February 2016. The head office of the Group is located at Sijun Road, (Wuzhou City), Zhejiang Province, China. The main business activities include medical services, etc.

On 15 October 2014, the Group was converted from a special non-profit cooperative enterprise to a public company (溫州康寧醫院股份有限公司 (Wuzhou Kangning Hospital Share Limited)).

The independent member of the Group's subsidiary (Wuzhou) is operated as a clinic operation point of the Group's medical services operation.

The Group is a public limited liability company established on 15 October 2015.

The company is a public limited liability company of the Wuzhou (065) Special Economic Zone. The company is registered in the Wuzhou Special Economic Zone (064(7)) and is a public limited liability company of the Wuzhou (064(13)) Special Economic Zone.

Reference to "we", "us" and "our" in the consolidated financial statements refer to the Group. Reference to "the company" in the consolidated financial statements refer to the company. Reference to "the Group" in the consolidated financial statements refer to the company.

The financial statements were approved by the Board of Directors of the Group on 26 December 2021.

2. Significant accounting policies and accounting estimates

The significant accounting policies and estimates applied by the Group in the preparation of financial statements are outlined in Note 28.

(1) Basis of preparation

The financial statements were prepared on the basis of the *Accounting Standards for Business Enterprises - Basic Standards*, the specific accounting standards issued by the Ministry of Finance on 15 February 2006 and the *Accounting Standards for Business Enterprises - Reference to Accounting Standards for Business Enterprises (AS)*.

The financial statements were prepared on a cost basis.

The *Accounting Standards for Business Enterprises* became effective on 3 December 2014. The financial statements were prepared on the basis of the accounting standards issued by the Ministry of Finance.

Notes to the Financial Statements

For the year ended 31 December 2022
(As approved by the Board of Directors)

2 Statement of significant accounting policies and accounting estimates (continued)

(2) Statement of compliance with the Accounting Standards for Business Enterprises

The management of the Group for the year ended 31 December 2022 has complied with the Accounting Standards for Business Enterprises, and the corresponding accounting policies and estimates are in accordance with the accounting standards and accounting estimates prescribed by the Ministry of Finance, for the year ended 31 December 2022.

(3) Accounting year

The Group's accounting year ends on 31 December.

(4) Recording currency

The Group's recording currency is the Renminbi (RMB). The recording currency of the Group's subsidiaries is the local currency of the respective countries in which they operate. All the Group's financial statements are presented in the recording currency of the Group.

(5) Business combinations

Business combinations through absorption of the controlled company

Controlled combinations are those business combinations where the acquirer has obtained control over the acquiree. The acquisition of controlled companies is accounted for as follows: the difference between the fair value of the acquiree's identifiable intangible assets, the difference between the fair value of the acquiree's identifiable intangible assets, the difference between the fair value of the acquiree's identifiable intangible assets, the difference between the fair value of the acquiree's identifiable intangible assets, the difference between the fair value of the acquiree's identifiable intangible assets and the fair value of the acquiree's identifiable intangible assets.



Notes to the Financial Statements

For the year ended 31st December 2020
(As approved by the Council of the Institute)

2. Summary of individual accounts and consolidated accounts (continued)

(6) Preparation of consolidated financial statements

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

2 Summary of significant accounting policies and accounting estimates (continued)

(7) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, deposits held with banks, and other short-term investments that are readily convertible into cash and are subject to an insignificant risk of change in value.

(8) Foreign currency translation

Foreign currency transactions

Foreign currency transactions are translated into the reporting currency using the exchange rate prevailing at the date of the transaction.

At the balance sheet date, monetary items denominated in foreign currencies are translated into the reporting currency using the reporting date of the balance sheet. Exchange differences arising from the translation are recognised in profit or loss for the reporting period, except for the attributable to foreign currency borrowings that are being used to purchase fixed assets or construction of assets, which are capitalised as part of the cost of the assets. Monetary items denominated in foreign currencies are translated into the reporting currency using the exchange rate prevailing at the balance sheet date of the reporting period. The effect of exchange rate fluctuations is recognised separately in the cash flow statement.

(9) Financial instruments

All financial assets and liabilities are initially recognised at the fair value of the financial instrument. All financial assets and liabilities are subsequently measured at amortised cost, except for those that are classified as held for sale.

(a) Held for sale

(i) Financial assets

Assets are classified as held for sale when they are available for sale in their current condition, and their carrying amount is measured at the lower of carrying amount and fair value less costs to sell. Assets are classified as held for sale when they are available for sale in their current condition, and their carrying amount is measured at the lower of carrying amount and fair value less costs to sell.

Assets are classified as held for sale when they are available for sale in their current condition, and their carrying amount is measured at the lower of carrying amount and fair value less costs to sell. Assets are classified as held for sale when they are available for sale in their current condition, and their carrying amount is measured at the lower of carrying amount and fair value less costs to sell.



E (A (S A L , L O .
A A L E

Notes to the Financial Statements

For the year ended 31 December 2022
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

2 Statement of financial position and statement of financial performance (continued)

(9) Financial instruments (continued)

(a) Hedge accounting (continued)

(ii) Pledged

For the year ended 31 December 2022, the company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

The company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

At the year end, the company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

For the year ended 31 December 2022, the company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

For the year ended 31 December 2022, the company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

For the year ended 31 December 2022, the company has pledged the following financial assets as collateral for the following financial liabilities: (continued)

Notes to the Financial Statements

For the year ended 31st December 2022
(As approved by the Board of Directors)

2 Statement of Financial Position and Statement of Financial Performance (continued)

(9) Financial instruments (continued)

- (a) Hedge reserve (continued)
- (ii) Derivatives (continued)

The Group's EBITDA includes the net result of derivative contracts entered into for hedging purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for speculative purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for hedging purposes.

Accumulated losses on derivatives	Loss on derivatives
Accumulated gains on derivatives	Gain on derivatives
Accumulated losses on derivatives	Gain on derivatives
Accumulated gains on derivatives	Loss on derivatives
Accumulated losses on derivatives	Gain on derivatives
Accumulated gains on derivatives	Loss on derivatives

The Group's EBITDA includes the net result of derivative contracts entered into for hedging purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for speculative purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for hedging purposes.

Based on the above information, the Group's EBITDA includes the net result of derivative contracts entered into for hedging purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for speculative purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for hedging purposes.

The Group's EBITDA includes the net result of derivative contracts entered into for hedging purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for speculative purposes. The Group's EBITDA also includes the net result of derivative contracts entered into for hedging purposes.

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B.A. unless otherwise stated)

2. Summary of individual accounts and consolidated accounts (continued)

(9) Financial instruments (continued)

(a) Hedge derivatives (continued)

(iii) Receivables

Amounts are in Euro. (i) represents the amount of receivables from hedge derivatives



Notes to the Financial Statements

For the year ended 31st December 2024
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

2 Statement of Financial Position and Statement of Financial Performance (continued)

(11) Long-term equity investments

Long-term equity investments comprise of shares of equity instruments, and other long-term equity instruments.

Share investments are recorded at cost plus or minus adjustments. Adjustments include dividends received and other income or losses.

Equity investments are recorded at cost plus or minus adjustments. Adjustments include dividends received and other income or losses.

(a) Investment of cash

For the long-term equity investments, the cost of acquisition is the fair value of the consideration given, less any commission received.

For the long-term equity investments, the cost of acquisition is the fair value of the consideration given, less any commission received.

(b) Share investments in associates

Long-term equity investments in associates are recorded at cost plus or minus adjustments. Adjustments include dividends received and other income or losses.

For the long-term equity investments, the cost of acquisition is the fair value of the consideration given, less any commission received.

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B. M. unless otherwise stated)

2 Summary of significant accounting policies and accounting estimates (continued)

(12) Investment properties

Investment properties, which are held to generate cash flows, but not for sale, are measured at fair value less costs to sell. The fair value of investment properties is determined by reference to the market value of similar properties, adjusted for differences in location, size, age, etc. The fair value of investment properties is determined by reference to the market value of similar properties, adjusted for differences in location, size, age, etc. The fair value of investment properties is determined by reference to the market value of similar properties, adjusted for differences in location, size, age, etc.



Notes to the Financial Statements

For the year ended 31 December 2022

(As approved by the Board of Directors)

2 Statement of financial position and accounts (continued)

(13) Fixed assets

(a) *Accounting policies and methods*

Fixed assets comprise buildings, technical equipment, furniture, electronic equipment and other equipment.

Fixed assets are recorded at their probable realisable economic benefit, less losses to be recognised on disposal. Fixed assets are revalued at the lower of cost and fair value less costs to sell.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

Notes to the Financial Statements

For the year ended 31 December 2022
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

2 Summary of significant accounting policies and accounting estimates (continued)

(15) Borrowing costs (continued)

For the period borrowing costs are for the acquisition of construction of the new plant for capital asset, the amount of borrowing cost eligible for capitalization is determined by the cost of the borrowing less any income earned on the borrowing. For the period borrowing cost is the amount of the borrowing cost less any income earned on the borrowing.

For the amount of the borrowing cost eligible for capitalization is the amount of the borrowing cost less any income earned on the borrowing. For the period borrowing cost is the amount of the borrowing cost less any income earned on the borrowing.

(16) Intangible assets

The intangible assets are the identifiable intangible assets, of the nature and substance, which are identifiable as an asset.

(i) *Leasehold*

Leasehold is the amount of the identifiable intangible assets, of the nature and substance, which are identifiable as an asset.

(ii) *Software fee*

Software fee is the amount of the identifiable intangible assets, of the nature and substance, which are identifiable as an asset.

Notes to the Financial Statements

For the year ended 31st December 2018
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

2 Statement of Intangible Assets (continued)

(16) Intangible assets (continued)

(iii) Other intangible assets

Other intangible assets include the following: (i) Patents, (ii) Trademarks, (iii) Copyrights, (iv) Licences, (v) Software, (vi) Other intangible assets. The carrying amount of other intangible assets is disclosed in the following table:

The carrying amount of other intangible assets is disclosed in the following table:

	Carrying amount
Patents (cost) (₹) (₹)	₹
Trademarks (cost) (₹) (₹)	₹
Copyrights (cost) (₹) (₹)	₹

(i) Licences

Licences are the rights to use the intellectual property of others. The carrying amount of licences is disclosed in the following table:

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

2 Statement of Intangible Assets

(16) Intangible assets

(ii) Intangible assets

Intangible assets include the costs of research and development of new products, which are amortised over their useful lives. The useful lives are estimated to be between 5 and 10 years. The carrying amount of intangible assets is disclosed in the following table.

Intangible assets are primarily related to the acquisition of intangible assets from the acquisition of subsidiaries. The carrying amount of intangible assets is disclosed in the following table.

Notes to the Financial Statements

For the year ended 31 December 2022
 (As approved by the Board of Directors)

2 Summary of significant accounting policies and accounting estimates (continued)

(17) Long-term prepaid expenses

Long-term prepaid expenses are payments for products or services that are expected to be used over a period exceeding 12 months. Long-term prepaid expenses are recorded as assets on the balance sheet and are expensed as the period of benefit of the asset expires. Long-term prepaid expenses are recorded as assets on the balance sheet and are expensed as the period of benefit of the asset expires.

(18) Impairment of long-term assets

Revenues, contracts, and other long-term assets are reviewed for impairment at the end of each reporting period. Impairment is identified when the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the maximum of the asset's fair value less costs of disposal and its value in use. The carrying amount of an asset is written down to its recoverable amount. An impairment loss is recognized if the carrying amount of an asset exceeds its recoverable amount. An impairment loss is recognized in the profit or loss account for the period in which the impairment occurs.

Goodwill is tested for impairment at the end of each reporting period. Goodwill is tested for impairment by comparing the carrying amount of the cash-generating unit to its recoverable amount. If the carrying amount of the cash-generating unit exceeds its recoverable amount, the excess is recognized as an impairment loss. Goodwill is tested for impairment by comparing the carrying amount of the cash-generating unit to its recoverable amount. If the carrying amount of the cash-generating unit exceeds its recoverable amount, the excess is recognized as an impairment loss.

When the carrying amount of an asset exceeds its recoverable amount, the excess is recognized as an impairment loss in the profit or loss account.

(19) Employee benefits

Employee benefits refer to a form of compensation or remuneration in addition to the basic salary and wages for the services rendered by employees. Employee benefits include long-term employee benefits, short-term employee benefits, defined contribution plans, and defined benefit plans.

(a) Short-term employee benefits

Short-term employee benefits include salaries, bonuses, and other benefits, including vacation pay, sick pay, and other benefits. Short-term employee benefits are recognized as liabilities in the accounts payable and accrued liabilities account. Short-term employee benefits are recognized as liabilities in the accounts payable and accrued liabilities account.

Notes to the Financial Statements

For the year ended 31 October 2020
 (As approved by the Board of Directors)

2 Statement of financial position and accounts and notes (continued)

(19) Employee benefits (continued)

(b) Long-term benefits

The long-term provision for benefits payable is the sum of the employee contribution payable on the employee contribution payable and the employer contribution payable on the employee contribution payable. The employee contribution payable on the employer contribution payable is the employer contribution payable; the employer contribution payable on the employee contribution payable is the employee contribution payable. The employee contribution payable on the employer contribution payable is the employer contribution payable.

(c) Basic pension

The employee pension payable is the basic pension payable and the employee pension payable. The employee pension payable is the employee pension payable and the employer pension payable. The employee pension payable is the employee pension payable and the employer pension payable.

(20) Dividend distribution

The dividend distribution is the dividend payable and the dividend payable.

(21) Provisions

The provision for contingent liabilities is the provision for contingent liabilities and the provision for contingent liabilities.

A provision for contingent liabilities is the provision for contingent liabilities and the provision for contingent liabilities.

The provision for contingent liabilities is the provision for contingent liabilities and the provision for contingent liabilities.

The provision for contingent liabilities is the provision for contingent liabilities and the provision for contingent liabilities.

Notes to the Financial Statements

For the year ended 31 October 2024
 (Approved by the Board of Directors)

2 Summary of significant accounting policies and accounting estimates (continued)

(22) Share-based payments

(a) Expense of share-based payments

All share-based payments are accounted for as an expense in the profit or loss statement at the time of the grant, measured at the fair value of the equity instrument granted at the time of grant. The expense is recognised over the period of the service provided, or the vesting period, of the equity instrument. Share-based payments are classified as either equity-settled share-based payments or cash-settled share-based payments. For the year ended 31 October 2024, the company has only equity-settled share-based payments.

The company recognises the expense in the profit or loss statement for the expense of the equity instrument granted, which is measured at the fair value of the equity instrument at the time of grant. For cash-settled share-based payments, the expense is recognised over the vesting period, and the expense is recognised in the profit or loss statement at the time of the service provided, or the vesting period, of the equity instrument. The expense is recognised in the profit or loss statement at the time of the service provided, or the vesting period, of the equity instrument. The expense is recognised in the profit or loss statement at the time of the service provided, or the vesting period, of the equity instrument.

(b) Expense of the cash-settled share-based payments

The expense of the cash-settled share-based payments is the difference between the fair value of the equity instrument at the time of grant and the fair value of the equity instrument at the time of the service provided, or the vesting period, of the equity instrument.

(c) Basis for the expense of the equity-settled share-based payments

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

2 Summary of significant accounting policies and accounting estimates (continued)

(23) Revenue recognition

Notes to the Financial Statements

For the year ended 31 December 2022
 (As approved by the Board of Directors)

2 Statement of financial position and statement of financial performance (continued)

(24) Government grants

Government grants refer to the amount of the grant received by the Group from the government, including grants, subsidies, etc.

Government grants receivable are classified as either non-reciprocal or reciprocal conditions. For government grants with non-reciprocal conditions, the grant is recognized as income when the grant is received or receivable. For government grants with reciprocal conditions, the grant is recognized as income when the grant is received, the related liability is settled, or the liability is extinguished.

Government grants refer to the amount of the grant received by the Group from the government, including grants, subsidies, etc. Government grants are recognized as income when the grant is received or receivable.

Government grants refer to the amount of the grant received by the Group from the government, including grants, subsidies, etc. Government grants are recognized as income when the grant is received or receivable.

Government grants refer to the amount of the grant received by the Group from the government, including grants, subsidies, etc. Government grants are recognized as income when the grant is received or receivable.

Notes to the Financial Statements

For the year ended 31 December 2024
(As approved by the Board of Directors)

25. Significant accounting policies and accounting estimates (continued)

(25) Deferred tax assets and deferred tax liabilities (continued)

Deferred tax liabilities are recognised for temporary differences arising from taxable intangible assets, and are subject to the recognition criteria for deferred tax liabilities. Where it is probable that taxable temporary differences will exist in the future, and there is no deductible temporary differences available, a deferred tax liability is recognised for the temporary difference. Deferred tax liabilities are recognised for taxable temporary differences arising from intangible assets, and are subject to the recognition criteria for deferred tax liabilities. Where it is probable that taxable temporary differences will exist in the future, and there is no deductible temporary differences available, a deferred tax liability is recognised for the temporary difference. Deferred tax liabilities are recognised for taxable temporary differences arising from intangible assets, and are subject to the recognition criteria for deferred tax liabilities. Where it is probable that taxable temporary differences will exist in the future, and there is no deductible temporary differences available, a deferred tax liability is recognised for the temporary difference.

Deferred tax assets and deferred tax liabilities are offset if:

- the deferred taxes are related to the same tax payer within the Group and the same taxation authority; and,
- that tax payer within the Group has a legally enforceable right to offset current tax assets against current tax liabilities.

(26) Leases

A contract is, or contains, a lease if it conveys a right to control the use of an identified asset for a period of time in exchange for consideration.

Lease classification

A lease contract is classified as a finance lease if it transfers substantially all the risks and rewards of ownership of an underlying asset to the lessee. Lease contracts are classified as operating leases if they do not transfer substantially all the risks and rewards of ownership of an underlying asset to the lessee. Lease contracts are classified as operating leases if they do not transfer substantially all the risks and rewards of ownership of an underlying asset to the lessee. Lease contracts are classified as operating leases if they do not transfer substantially all the risks and rewards of ownership of an underlying asset to the lessee. Lease contracts are classified as operating leases if they do not transfer substantially all the risks and rewards of ownership of an underlying asset to the lessee.

Finance leases are those leases in which the lessee assumes substantially all the risks and rewards of ownership of an underlying asset. Finance leases are those leases in which the lessee assumes substantially all the risks and rewards of ownership of an underlying asset. Finance leases are those leases in which the lessee assumes substantially all the risks and rewards of ownership of an underlying asset. Finance leases are those leases in which the lessee assumes substantially all the risks and rewards of ownership of an underlying asset.

For more information, refer to page 120 of the 2024 Report. (a) .5(0) .5(0) .5(0) .5(0) .5(0) .5(0) .6(0) .5(0) .5(0) .6(0) .5(0) .5(0)

Notes to the Financial Statements

For the year ended 31 December 2020
 (A) Note 10 (B) Note 10 (continued)

2 Segment information

(27) Segment information

The reportable operating segments are based on the way our divisions manage their operations and are reported separately, and are based on the way the divisions are managed internally. The basis of operation is as follows:

All operating segments are composed of the reportable units of the following conditions: (1) the composition is based on the nature of the products, services and activities; (2) the operating segments are identifiable based on the reportable units of the divisions and the nature of the products, services and activities; and (3) financial information of the divisions, operating segments and financial data are based on the reportable units of the divisions and the economic characteristics of the divisions can be distinguished from the other operating segments.

(28) Critical accounting estimates and judgements

The reportable units are critical accounting estimates and judgements applied based on the information provided to the management of the divisions and are believed to be reasonable and accurate.

(a) Critical accounting estimates and judgements

Critical accounting estimates and judgements are significant risks of cash flows and adjustments to the cash flows of the divisions in the financial statements are as follows:

(i) Allowance for impairment of contract and unproven reserves

At 31 December 2020, the cash flows of contract and unproven reserves are reported to the Board of Directors (31 December 2019: B45,162,735). The allowance for impairment of contract and unproven reserves is based on the cash flows of contract and unproven reserves and is believed to be reasonable. The recoverability of the contract and unproven reserves is evaluated based on the financial condition of the divisions and the nature of the divisions and the projections of cash flows of the divisions of contract and unproven reserves.

The reportable units are critical accounting estimates and judgements applied based on the information provided to the management of the divisions and are believed to be reasonable and accurate.

Notes to the Financial Statements

For the year ended 31 December 2020
(Amount in million RMB unless otherwise specified)

2 Significant accounting policies, accounting estimates and accounting judgements (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Significant accounting estimates and judgements (continued)

(i) Allowance for impairment of collateral and provision for doubtful receivables (continued)

2020, the management adopted the economic recoverability of the collateral and provision for doubtful receivables as the key estimates and judgements:

	Yiwu Health Centre		Pujiang Hospital
Allowance for unpaid bills in operation*	362		274
Allowance for unpaid bills in operation**	266		247
Provision*	6%		16%
Percentage of collateral	0.11%		1.5%
Percentage of impairment	2.5%		2.5%

2019, the management adopted the economic recoverability of the collateral and provision for doubtful receivables as the key estimates and judgements:

	Yiwu Health Centre	Pujiang Hospital and Chun'an Hospital
Allowance for unpaid bills in operation*	373	233
Allowance for unpaid bills in operation**	283	24
Provision*	6%	33%
Percentage of collateral	1.37%	1.4%
Percentage of impairment	3%	3%

* Represents the allowance for bills in operation.

2020, the management adopted the collateral and provision based on the principle of fair value for each of the bills in operation, and adopted the economic recoverability of the collateral and provision for doubtful receivables as the key estimates and judgements. The management adopted the impairment loss based on the principle of fair value for each of the bills in operation, and adopted the economic recoverability of the collateral and provision for doubtful receivables as the key estimates and judgements. For the year ended 31 December 2020, the provision for impairment of collateral and provision for doubtful receivables is as follows:

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

2. Summary of significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Significant accounting estimates and judgements (continued)

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

2 Significant accounting policies adopted and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Significant accounting estimates and judgements (continued)

(iii) Measurement of fair value of the property

The property (note 46) are measured at fair value using the discounted cash flow method. The significant inputs are, discount rate, etc.

The measurement of fair value of the property is as follows:

	Fair value as at 31 December 2020	Valuation technique	Significant unobservable inputs			
			Name	Weighted average	Relationship with fair value	Observable/ Unobservable
Value of Buildings held for sale at end of year	42,628,66	Discounted cash flow	Ultimate return rate/ discount rate (8.00%) vacancy rate (2.74%)	5.0 % 48.51	(a)	Unobservable
Value of Buildings held for sale at end of year	65,176,80	Discounted cash flow	Ultimate return rate/ discount rate (8.50%) vacancy rate	50.0 % 0.5-33	(a)	Unobservable
	107,805,46					

i) Accounting for the effects of the discount rate of the property is as follows:

(a) The relationship between the unobservable inputs and the fair value is:

- the higher the ultimate return rate/capitalisation rate is, the lower the fair value is;
- the higher the estimated vacancy rate is, the lower the fair value is;
- the higher the monthly rental is, the higher the fair value is.

Notes to the Financial Statements

For the year ended 31 December 2020
 (A) (continued) (B) (continued)

2 Summary of significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Significant accounting estimates and judgements (continued)

(i) Accounting estimates of provisions

The Group has made provisions for liabilities and contingent liabilities. The recognition of provisions for liabilities is based on the Group's assessment of the probability of an outflow of resources in the form of cash or other assets. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources.

The Group has made provisions for liabilities and contingent liabilities. The recognition of provisions for liabilities is based on the Group's assessment of the probability of an outflow of resources in the form of cash or other assets. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources.

The Group has made provisions for liabilities and contingent liabilities. The recognition of provisions for liabilities is based on the Group's assessment of the probability of an outflow of resources in the form of cash or other assets. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources.

The Group has made provisions for liabilities and contingent liabilities. The recognition of provisions for liabilities is based on the Group's assessment of the probability of an outflow of resources in the form of cash or other assets. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources.

The Group has made provisions for liabilities and contingent liabilities. The recognition of provisions for liabilities is based on the Group's assessment of the probability of an outflow of resources in the form of cash or other assets. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources. The Group's assessment is based on the Group's current estimates of the amount and timing of the outflow of resources.

Notes to the Financial Statements

For the year ended 31 December 2022
(As approved by the Board of Directors)

2 Significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(a) Significant accounting estimates and judgements (continued)

(i) Goodwill and intangible assets

The primary objective of goodwill and intangible asset impairment testing is to determine whether the carrying amount of the cash-generating unit exceeds its recoverable amount. Significant judgement is required to estimate the cash-generating unit's recoverable amount. The carrying amount of goodwill and intangible assets is determined as the difference between the acquisition cost and the fair value of the identifiable intangible assets.

Intangible assets are reviewed for impairment whenever there are indications that the carrying amount may not be recoverable. Indications that the carrying amount may not be recoverable include: (a) the carrying amount of the intangible asset exceeds its cash-generating unit's carrying amount; (b) the carrying amount of the intangible asset exceeds the cash-generating unit's carrying amount; (c) the carrying amount of the intangible asset exceeds the cash-generating unit's carrying amount; (d) the carrying amount of the intangible asset exceeds the cash-generating unit's carrying amount. An impairment loss is recognized if the carrying amount of the intangible asset exceeds its recoverable amount.

(b) Significant accounting estimates and judgements

(i) Goodwill and intangible assets (continued)

The primary objective of goodwill and intangible asset impairment testing is to determine whether the carrying amount of the cash-generating unit exceeds its recoverable amount. Significant judgement is required to estimate the cash-generating unit's recoverable amount.

A significant portion of the cash-generating unit's recoverable amount is derived from the cash-generating unit's operations. The carrying amount of the cash-generating unit is determined as the difference between the acquisition cost and the fair value of the identifiable intangible assets. An impairment loss is recognized if the carrying amount of the cash-generating unit exceeds its recoverable amount.

Notes to the Financial Statements

For the year ended 31 October 2020
(A Group of Companies and its subsidiaries)

2 Summary of significant accounting policies and accounting estimates (continued)

(28) Critical accounting estimates and judgements (continued)

(b) Significant accounting policies (continued)

(ii) Significant accounting estimates

Estimates of the carrying amount of significant receivable assets are based on the expected recoverable net realisable value, or the expected value of the remaining contractual rights to significant receivable assets. The determination of the recoverable net realisable value, significant receivable assets, expected operating results, significant receivable value of contracts, etc.

Estimates of the probability of occurrence of significant liabilities are based on the expected value of the expected net realisable value (i.e., the expected net realisable value), or the expected value of the remaining contractual rights to significant receivable assets, etc.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

3. Taxation

The major categories of tax applicable to the Group are as follows:

Category	Tax rate	Tax base
Corporate income tax (a)	15%, 20% or 25%	Adjusted taxable income
Dividend income (b)	1%, 3%, 5%, 6% or 13%	Dividend income
Interest income	7%	Amount of A taxable income paid
Employer's social security	3%	Amount of A taxable income paid
Local employer's social security	2%	Amount of A taxable income paid
Corporate tax (c)	12% or 12%	0% of total amount of corporate income tax
Substantial shareholding (d)	5%	Dividend
Dividend A	0% - 0%	Amount of dividend

(a) From 1 December 2020, the income tax rate for corporations is, respectively, 15% for companies with a taxable income of up to 200 million euros, 20% for companies with a taxable income between 200 million and 500 million euros, and 25% for companies with a taxable income exceeding 500 million euros. The amount of the tax is calculated on the taxable income of the company as determined in accordance with the provisions of the Income Tax Law of 2017 (Law No. 4476/2017).

In accordance with the Income Tax Law of 2017, the tax rate for companies with a taxable income of up to 200 million euros is 15%. The amount of the tax is calculated on the taxable income of the company as determined in accordance with the provisions of the Income Tax Law of 2017 (Law No. 4476/2017). The amount of the tax is calculated on the taxable income of the company as determined in accordance with the provisions of the Income Tax Law of 2017 (Law No. 4476/2017). The amount of the tax is calculated on the taxable income of the company as determined in accordance with the provisions of the Income Tax Law of 2017 (Law No. 4476/2017).

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

3. Taxation (continued)

(b) (continued)

The amount approved for the year-end effective tax rate of 3% is based on the effective tax rate of 3% of the taxable income of the Company for the year ended 31 December 2020. The amount approved for the year-end effective tax rate of 1% is based on the effective tax rate of 1% of the taxable income of the Company for the year ended 31 December 2020.

The amount approved for the year-end effective tax rate of 13% is based on the effective tax rate of 13% of the taxable income of the Company for the year ended 31 December 2019. The amount approved for the year-end effective tax rate of 16% is based on the effective tax rate of 16% of the taxable income of the Company for the year ended 31 December 2018.

(c) The amount of the provision for the year ended 31 December 2020 is based on the provision for the year ended 31 December 2019, which was based on the provision for the year ended 31 December 2018.

The amount of the provision for the year ended 31 December 2020 is based on the provision for the year ended 31 December 2019, which was based on the provision for the year ended 31 December 2018.

(*) The amount of the provision for the year ended 31 December 2020 is based on the provision for the year ended 31 December 2019, which was based on the provision for the year ended 31 December 2018.

The amount of the provision for the year ended 31 December 2020 is based on the provision for the year ended 31 December 2019, which was based on the provision for the year ended 31 December 2018.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Notes to the consolidated financial statements

(1) Cash at bank and on hand

	31 December 2020	31 December 2019
Cash at bank	374,287	45,334
Cash on hand	206,125,277	175,377,404
Prepaid expenses	-	13,222
	206,499,564	175,795,960

As at 31 December 2020, the effective cash and cash equivalents of B6,068,000 represent the prepayment for construction project of the 120 MW (plus) substation of the project.

As at 31 December 2019, the effective prepayment of B0,000, the effective cash of B110,68,000 represent the prepayment applied by the Project Finance Company to the construction project.

(2) Accounts receivable

	31 December 2020	31 December 2019
Accounts receivable (note 8(5)(a))	7,250,000	8,200,000
Accounts payable	348,065,571	30,174,215
Subsidiary	355,315,571	338,424,215
Less: provision for bad debts	(33,907,606)	(27,030,000)
	321,407,965	30,568,430

Accounts receivable are primarily trade receivables.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Notes to the financial statements (continued)

(2) Accounts receivable (continued)

(a) The carrying amount of accounts receivable based on the ageing analysis is as follows:

	31 December 2020	31 December 2019
within 1 year	276,029,265	266,323,53
1 to 2 years	59,715,117	57,88,07
2 to 3 years	19,442,357	13,8,001
over 3 years	128,832	413,854
	355,315,571	338,424,215

2020, the company's accounts receivable are recoverable for the purpose of the financial statements.

(b) Provision for bad debts

The company has determined the allowance for accounts receivable based on the ageing analysis, the nature of the receivables and the historical experience of the company.

At 31 December 2020, the company's accounts receivable are provisioned for bad debts at a provision of HK\$128,832 (31 December 2019: HK\$413,854).

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4 Notes to the financial statements (continued)

(2) Accounts receivable (continued)

(b) Provision for bad debts (continued)

- (i) Accounts receivable for which the provision for bad debts is a provision of the balance sheet as follows:

	31 December 2020			31 December 2019		
	Book value	Provision for bad debts		Book value	Provision for bad debts	
	Amount	Lifetime ECL rate	Amount	Amount	Lifetime ECL rate	Amount
Government related	29,027,823	1%	290,278	23,148,088	1%	231,148
Government related	169,414,663	4%	6,776,587	151,536,144	5%	7,576,077
Individual	77,586,779	4%	3,103,471	10,266,664	6%	5,465,500
Individual	59,715,117	20%	11,943,024	57,614,783	11%	6,337,626
Individual	19,442,357	60%	11,665,414	11,627,088	0%	5,813,354
Individual	128,832	100%	128,832	413,854	0%	413,854
Total	355,315,571		33,907,606	336,534,611		26,143,349

- (ii) The amount of provision for bad debts for the year ended 31 December 2020 is B23,414,275 (2019: B2,616,274), and B72,787 (2019: B25,860).

The book value of accounts receivable and related off-balance sheet receivables is B17,337,485, and the provision for bad debts is B17,337,485, and the net amount of receivables of the year ended 31 December 2020 is B0.

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4 Other receivables and advances (continued)

(3) Other receivables

	31 December 2020	31 December 2019
Loans to subsidiaries (i)	11,623,500	21,283,00

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Other receivables (continued)

(3) Other receivables (continued)

(a) Breakdown of other receivables by category:

	31 December 2020	31 December 2019
Stage 1	20,302,805	21,336,124
Stage 2	18,699,660	1,781,477
Stage 3	4,964,193	2,351,166
Stage 3	24,282,668	24,885,514
	68,249,326	75,465,781

(b) Provision for impairment losses on book value:

	Stage 1 12-month ECL (on the grouping basis)		Stage 3 Lifetime ECL (credit-impaired)		Total Provision for bad debts
	Book value	Provision for bad debts	Book value	Provision for bad debts	
31 December 2020	65,404,466	3,112,215	2,752,855	2,014,220	12,148,415
Decrease in provision	15,334,712	2,410,777		488,428	1,414,305
Initial provision					

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Other receivables (continued)

(3) Other receivables (continued)

(b) Provision for one-off credit impairment losses (continued)

(i) As at 31 December 2020, for one-off credit impairment losses under Stage 1, the effective provision for bad debts is as follows:

	Book value	12-month ECL rate	Provision for bad debts
Provision for one-off bad debts:			
Loan portfolio	11,623,00	7%	813,645
Advance	8,75,352	7%	628,275
Credit impairment portfolio	26,113,638	5%	1,305,682
Provision for one-off bad debts	8,682,06	3%	260,46
Total	45,174,015	1%	3,008,068
	60,33,211		3,110,55

(ii) As at 31 December 2020, the provision for one-off credit impairment losses under Stage 2:

(iii) As at 31 December 2020, for one-off credit impairment losses under Stage 3, the effective provision for bad debts is as follows:

	Book value	Lifetime ECL rate	Provision for bad debts
Provision for one-off bad debts:			
Loan portfolio (Total)	2,156,115	7%	1,50,848

(i) The one-off credit impairment losses under Stage 1 are provided for the loan portfolio. The effective provision for one-off credit impairment losses under Stage 1 is as follows: As at 31 December 2020, the one-off credit impairment losses under Stage 1 are provided for the loan portfolio. The effective provision for one-off credit impairment losses under Stage 1 is as follows: As at 31 December 2020, the one-off credit impairment losses under Stage 1 are provided for the loan portfolio. The effective provision for one-off credit impairment losses under Stage 1 is as follows:

(c) 2020, the one-off credit impairment losses under Stage 1 are provided for the loan portfolio. The effective provision for one-off credit impairment losses under Stage 1 is as follows: As at 31 December 2020, the one-off credit impairment losses under Stage 1 are provided for the loan portfolio. The effective provision for one-off credit impairment losses under Stage 1 is as follows:

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Other receivables and advances (continued)

(4) Advances to suppliers

(a) Breakdown of receivables and advances by category:

	31 December 2020		31 December 2019	
	Amount	% of total balance	Amount	% of total balance
in 1 year	11,747,540	98%	5,258,821	98%
1-2 years	93,133	1%	2,553	
2-3 years	20,209	-	54,646	1%
over 3 years	67,000	1%	3,000	1%
	11,927,882	100%	5,366,020	100%

(5) Inventories

(a) Breakdown of inventories by category:

	31 December 2020	31 December 2019
Manufactured products	28,767,481	17,382,132
Raw materials	6,165,704	3,038,818
Provision for impairment	2,575,286	2,575,286
	37,508,471	23,568,236

As at 31 December 2020 and 31 December 2019, the amount of the provision for impairment on raw materials is zero.

As at 31 December 2020, the carrying amount of inventories is: (i).

(i) Provision for impairment

Project name	Provision		31 December 2020	31 December 2019
	at the beginning of the year	at the end of the year		
Project of B.M.E. S.A.	2,575,286	2,575,286	2,575,286	2,575,286

As at 31 December 2020, the provision for impairment is zero.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Notes to the consolidated financial statements (continued)

(5) Inventories (continued)

(b) The following table sets out the carrying amounts of the following:

	31 December 2020	31 December 2019	Decrease	Increase	31 December 2020
	€ million	€ million	€ million	€ million	€ million
Raw materials	17,383,132	81,003	214,632,220	(204,73,524)	28,767,481
Work in progress	3,033,818	223,76	58,6057	(56,658,147)	6,165,704
Finished goods	2,575,286				2,575,286
	23,568,236	104,357	273,628,327	(205,731,671)	37,508,471

(6) Current portion of non-current assets

	31 December 2020	31 December 2019
Prepaid expenses (i)	-	12,688,04

(i) Prepaid expenses represent the amount paid by the Group to the service providers for the execution of the projects. The prepaid expenses represent the amount paid by the Group to the service providers for the execution of the projects. The prepaid expenses represent the amount paid by the Group to the service providers for the execution of the projects. The prepaid expenses represent the amount paid by the Group to the service providers for the execution of the projects.

(7) Long-term equity investments

	31 December 2020	31 December 2019
Alodae (a)	93,726,511	8,433,13
Investment in joint venture	-	-
	93,726,511	8,433,13

The investment in Alodae is classified as a long-term equity investment.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. **Other economic indicators** (continued)

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4. Non-current assets and liabilities (continued)

(10) Fixed assets (continued)

(a) The non-current assets of the Company, the amount of which is presented in each of the following tables, are classified as follows:

	2020	2019
Property, plant and equipment	34,129,808	26,587,185
Intangible assets	6,525,635	7,767,122
Financial assets		

Notes to the Financial Statements

For the year ended 31 December 2024
 (As approved by the Board of Directors)

4. Other non-current assets and liabilities (continued)

(12) Right-of-use assets

	Buildings
31 December 2024	265,171,600
Decrease in carrying amount due to depreciation	(33,033,772)
Increase in carrying amount due to lease modification	311,000
Balance carried forward from the previous year's consolidated financial statements (note 5(1)(c))	4,528,666
Decrease in carrying amount due to impairment	(13,711,800)
31 December 2023	290,544,319
Accumulated depreciation	
31 December 2024	2,855,521
Provision	33,116,514
31 December 2023	62,976,040
31 December 2022	227,568,279
31 December 2021	235,312,140

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Intangible assets (continued)

(13) Intangible assets

	Land use rights	Software	Contractual right to provide management services	Licences	Trademark rights	Total
31 December 2020	36,455,400	2,253,611	51,074,413	55,837,000		153,457,414
Decrease in carrying amount						
Impairment	27,070,000	10,388,446			2,829,386	31,574,832
Balance carried forward in respect of intangible assets (note 5(1)(c))		537,111		27,000,000		27,537,111
Decrease in carrying amount			(14,333,544)			(14,333,544)
31 December 2020	64,166,940	10,828,626	36,973,869	82,837,000	2,829,386	197,635,821
Accumulated impairment						
31 December 2019	30,732,707	5,152,411	6,744,678	6,157,300		23,152,886
Decrease in carrying amount						
Impairment	10,757,774	1,666,348	2,681,111	2,232,088	4,207	14,017,748
Decrease in carrying amount			(2,161,411)			(2,161,411)
31 December 2019	6,173,771	6,828,639	6,650,848	15,396,628	49,207	35,099,093
Goodwill						
31 December 2020	57,993,169	3,999,987	30,323,021	67,440,372	2,780,179	162,536,728
31 December 2019	31,361,443	402,370	45,162,735	4,672,680		104,818,128

2020, the acquisition of intangible assets in respect of B14,017,748 (2019: B0,874,756). 2020, the amount of impairment expense in respect of goodwill, the amount of impairment expense in respect of intangible assets in respect of B11,652,616, B2,383,232 and B57,022, respectively (2019: B902,203, B1,865,353 and B0).

(i) The impairment of goodwill in respect of the acquisition of 16. The amount of goodwill impairment in respect of 15 of Feb 2020 46. The amount of impairment, the proportion of goodwill impairment in respect of (i) the amount of goodwill impairment in respect of 16. Accounts in respect of, the proportion of goodwill impairment in respect of 16.

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4. Intangible Assets and Goodwill (continued)

(14) Goodwill

	31 December 2019	Decrease during the year (note 5)	31 December 2020
Goodwill			
Initial recognition	8,533,389		8,533,389
Goodwill disposal	7,784,850		7,784,850
Goodwill disposal	9,271,800		9,271,800
Goodwill disposal	22,987,331		22,987,331
Goodwill disposal	5,068,960		5,068,960
Goodwill disposal	6,843,289		6,843,289
Goodwill disposal		11,822,030	11,822,030
Goodwill disposal		13,448,538	13,448,538
Total	2,390,403		2,390,403
Sub-total	62,880,222	25,270,568	88,150,590
Less: liability for disposal			
Initial recognition	(8,533,389)		(8,533,389)
Goodwill disposal		(8,011,603)	(8,011,603)
Sub-total	(8,533,389)	(8,011,603)	(16,544,992)
	54,346,633	17,258,965	71,605,598

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Intangible Assets (continued)

(14) Goodwill (continued)

(a) A portion of the goodwill has been allocated to the cash generating units of the Group. The fair value of the cash generating units is determined by the cash flow projections of the units, which are based on operating performance forecasts:

	31 December 2020	31 December 2019
Intangible assets		
Goodwill (original)	9,271,800	9,271,800
Goodwill (original)	7,784,850	7,784,800
Goodwill (original)	22,987,331	22,987,331
(Goodwill 85% ((Intangible assets) @ -1.50%) 68,050,188	22,030	(Intangible assets)

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. **Other economic activities and related (income)**

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4. Other non-current assets and liabilities (continued)

(16) Deferred tax assets and deferred tax liabilities

(a) Deferred tax

	31 December 2020	
	Deductible temporary differences and deductible losses	Deferred tax assets
Accruals	122,695,044	30,673,761
Provision for doubtful debts	38,721,119	9,680,280
Share-based payment expense	16,899,060	4,224,765
Accruals related to property and equipment of joint-venture and provision of share-based payment liability	126,654	31,664
	7,865,404	1,966,351
	186,307,281	46,576,821
Provision:		
Expense to be recognized in the year (note)		9,680,280
Expense to be recognized in the year		36,896,541
		46,576,821
	31 December 2019	
	Deductible temporary differences and deductible losses	Deferred tax assets
Accruals	126,453,168	31,614,722
Provision for doubtful debts	40,520,181	10,130,066
Share-based payment expense	11,113,520	2,773,880
Accruals related to property and equipment of joint-venture and provision of share-based payment liability	126,654	31,664
Provision	5,346,351	1,336,588
	200,000	50,000
	185,037,114	46,275,900
Provision:		
Expense to be recognized in the year (note)		1,520,467
Expense to be recognized in the year		35,755,463
		46,275,900

Notes to the Financial Statements

For the year ended 31 December 2020
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

4 (16) Deferred tax assets and deferred tax liabilities (continued)

(16) Deferred tax assets and deferred tax liabilities (continued)

(b) Deferred liabilities

	31 December 2020	
	Taxable temporary differences	Deferred tax liabilities
Appreciation of real estate	91,613,072	22,903,268
Deferred compensation	8,516,685	2,129,171
	100,129,757	25,032,439
Net:		
Expected benefits in the future (net)		2,572,269
Expected benefits of the future		22,460,170
		25,032,439

	31 December 2019	
	Taxable temporary differences	Deferred tax liabilities
Appreciation of real estate	82,570,122	20,644,753
Deferred compensation	1,174,622	472,365
	84,466,474	21,124,118
Net:		
Expected benefits in the future (net)		2,455,167
Expected benefits of the future		18,668,951
		21,124,118

(c) Deferred tax assets and deferred tax liabilities (continued)

	31 December 2020	31 December 2019
Deferred tax assets	51,245,123	33,454,884

Notes to the Financial Statements

For the year ended 31 December 2020
 (As reported by the Board of Directors)

4 Other non-current assets and liabilities (continued)

(16) Deferred tax assets and deferred tax liabilities (continued)

(*) The table below shows the deferred tax assets and liabilities in the following table:

	31 December 2020	31 December 2019
20	-	8,646,75
21	8,766,673	5,838,726
22	11,852,360	6,37,80
23	651,018	1,62,585
24	9,667,426	0,338,718
25	20,307,646	
	51,245,123	33,454,884

(17) Other non-current assets

	31 December 2020	31 December 2019
Investment in subsidiaries	4,708,451	1,71,68
Investment (i)	14,000,000	
	18,708,451	1,71,68

(i) As at 31 December 2020, the balance of the investment of B14,000,000 is due from 15 April 2020 to 15 April 2022. The balance is held in the form of investment in the subsidiary of the company, which is a subsidiary of the company, and is held in the form of investment in the subsidiary of the company, and is held in the form of investment in the subsidiary of the company.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Other economic activities and additional items (continued)

(18) Provision for asset impairment and losses

	31 December 2019	Decrease Increase	Decrease Increase	31 December 2020
	TL	TL	TL	TL
Provision for bad debts of accounts receivable	27,033,033	23,414,275	(72,787)	33,907,606
Provision for bad debts of other receivable	12,148,415	1,413,055	(1,645,237)	4,813,513
Provision for impairment of loans	8,533,388	80,110,333		16,544,992
	48,585,077	32,855,383	(1,718,024)	55,266,111

(19) Short-term borrowings

	31 December 2020	31 December 2019
Short-term borrowings (other than (i))	312,500,000	20,000,000

- (i) As at 31 December 2019, the short-term borrowings consist of TL2,000,000 as short-term borrowings, TL1,000,000 (including other than (i)) as short-term borrowings; the short-term borrowings consist of TL20,000,000 as short-term borrowings, TL1,000,000 (including other than (i)); the short-term borrowings consist of TL20,000,000 as short-term borrowings, TL1,000,000 (including other than (i)).

As at 31 December 2019 and 31 December 2020, the effective rate of short-term borrowings is 40.5%-5.22% and 4.35%-5.22% respectively.

(20) Accounts payable

The details of accounts payable by economic activities are as follows:

	31 December 2020	31 December 2019
Interest payable	54,689,668	65,881,555
3 months	9,659,122	7,473,325
6 months	4,105,307	1,381,011
1 year	571,326	0,680
2-3 years	252,094	0,4816
over 3 years	296,410	20,613
	69,573,927	75,554,0

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Other non-current liabilities and provisions (continued)

(21) Contract liabilities

	31 December 2020	31 December 2019
Accounts receivable	12,965,170	8,562,126

At 31 December 2019, the contract liability of B8,562,126 represents the amount of revenue recognized in advance of the performance of the related services.

(22) Employee benefits payable

	31 December 2020	31 December 2019
Short-term employee benefits payable (a)	41,593,360	34,407,600
Employee contributions to defined pension plans (b)	1,191,773	1,522,587
	42,785,133	35,930,187

(a) Short-term employee benefits

	31 December 2020	31 December 2019	2020	2019	31 December 2020
Gratuity, bonus, and other benefits payable	33,064,488	7,802,800	4,802,612	(1,577,600)	40,453,010
Staff welfare	443,000	-	6,221,225	(6,647,000)	17,470
Social security contributions	813,536	1,271	0,838,145	(0,555,516)	1,115,436
Provision for vacation leave	716,324	1,002	0,624,221	(0,255,863)	1,103,684
Provision for sick leave	2,225	26	1,108	(20,822)	10,420
Provision for other leave	76,287	-	22,616	(7,571)	1,332
Provision for other employee benefits	5,615	-	14,352,645	(14,307,816)	7,444
Labour union funds for employee contributions	-	-	653,005	(653,005)	-
Short-term employee benefits	-	-	143,716	(143,716)	-
	34,407,600	817,402	30,235,588	(32,307,587)	41,593,360

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4 Other non-current liabilities and provisions (continued)

(22) Employee benefits payable (continued)

(b) Employee contribution payable

	31 December 2019	31 December 2020	Decrease/Increase	31 December 2020
	€	(€)	€	€
Basic pension contribution payable	1,553,111	17,132	8,610,000	1,166,779
Provision for employee benefits	3,576	612	233,774	24,994
	1,556,687	17,744	8,843,774	1,191,773

(c) Defined benefit payable

None, as no provision for defined benefit is made for the provision of employee benefits.

(23) Taxes payable

	31 December 2020	31 December 2019
Employee contribution payable	22,692,620	12,348,641
Income tax payable	4,826,592	623,371
Stamp duty	1,990,173	582,600
Stamp duty payable	18,110,608	18,407,711
Total	49,046,555	33,409,000

Notes to the Financial Statements

For the year ended 31 December 2020
 (As reported in the Budgetary Control System)

4 Other receivables and other payables (continued)

(24) Other payables

	31 December 2020	31 December 2019
Payable for projects (i)	27,016,438	55,017,768
Payable to other parties (see 8(5)(b))	12,870,241	28,417,713
01-440 (28,417,713) - 42.87 - other receivables		
640 01-444 (6,713) - 42.87 - other receivables		270,000

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4 Notes to the consolidated financial statements (continued)

(26) Long-term borrowings

	31 December 2020	31 December 2019
Bank and finance borrowings (a)	95,992,970	6,000,000
Bank prepayments (b)	18,000,000	
Less: unexpired portion of term finance borrowings (note 4(25))	(3,000,000)	(4,000,000)
	110,992,970	2,000,000

(a) As at 31 December 2020, the company's bank and finance borrowings consist of RMB5,992,970, of which RMB2,000,000 are bank and finance borrowings, and RMB3,992,970 are bank prepayments (note 4(4)). The bank and finance borrowings were issued on 16 April 2020 to 16 April 2023. The bank and finance borrowings consist of RMB2,000,000 are bank and finance borrowings, and RMB3,992,970 are bank prepayments (note 4(4)). The bank and finance borrowings were issued on 31 December 2019 to 31 December 2024, and the prepayments were repaid on 10 February 2022. The bank and finance borrowings consist of RMB4,000,000 are bank and finance borrowings, and RMB2,000,000 are bank prepayments (note 4(4)). The bank and finance borrowings were issued on 11 October 2019 to 11 October 2022.

(b) As at 31 December 2020, the balance of the company's bank prepayments amounting to RMB18,000,000 are prepayments 53.33% of the amount of RMB33,750,000 (original amount of RMB20,000,000, and RMB13,750,000 are bank and finance borrowings) and RMB14,250,000 are prepayments of the company (note 4(4)). The bank and finance borrowings were issued on 10 February 2022.

(c) As at 31 December 2020, the effective rate of term finance borrowings are 4.35% to 7.0% and (31 December 2019: 4.75% to 5.15%).

(27) Lease liabilities

	31 December 2020	31 December 2019
Lease liability	222,341,901	20,861,366
Less: unexpired portion of lease liability (note 4(25))	(32,540,617)	(27,532,181)
	189,801,284	183,081,151

As at 31 December 2020, the company's total lease liability balance is equal to the amount of the lease liability.

As at 31 December 2020, the company's total lease liability balance is equal to the amount of the lease liability.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Provisions, contingent liabilities and commitments (continued)

(28) Provisions

	31 December 2020	Provision recognised	31 December 2020
	2020	2020	2020
Provision for litigation (i)	200,000	(200,000)	-

- (i) As at 31 December 2020, the liability of the proposed Singapore Fund (op) (see 4(13)) is fully provided for. The proposed B200,000 of Singapore Fund (op) is based on the best estimate. As at 31 December 2020, the proposed liability of litigation costs is based on the proposed B200,387 of Singapore Fund (op).

(29) Deferred income

	31 December 2020	31 December 2019
Deferred income	9,645,475	9,342,267

	31 December 2020	31 December 2019	Attributable to equity holders
Deferred income - projects	9,645,475	9,342,267	Attributable to equity holders
Proposed projects of the proposed biotech (i)	9,645,475	9,342,267	Attributable to equity holders

- (i) The deferred income is attributable to the proposed biotech of B0,632,80 for the proposed projects of the proposed biotech (see 4(13)). The proposed deferred income is based on the best estimate of the expected life of the proposed biotech. The proposed deferred income is based on the best estimate of the expected life of the proposed biotech. The proposed deferred income is based on the best estimate of the expected life of the proposed biotech.

(30) Share capital

	31 December 2020	31 December 2019
Share capital (i)	75,60,000	74,60,300

- (i) In 2020, the proposed share of 89,000 of the proposed biotech. The proposed share of 89,000 of the proposed biotech. The proposed share of 89,000 of the proposed biotech.

Notes to the Financial Statements

For the year ended 31 December 2020

(As approved by the Board of Directors on 18 February 2021)

4 Notes to the financial statements additional disclosures (continued)

(31) Capital surplus

	31 December 2019	Increase/ Decrease	Decrease/ Increase	31 December 2020
Share premium (i)	775,663,317	1,680,633	(27,438,582)	749,889,082
Share-based payments (ii)	0,000,000	5,887,033	(0,000,000)	16,710,203
Reserves (ii)	38,155,465		(188,221)	37,967,244
	824,715,445	7,585,666	(27,734,582)	804,566,529

(i) The amount for the decrease in the share premium of capital surplus is 27,438,582. This has been recorded in the Profit and Loss account and the consolidated statement of financial position of 31 December 2020. The increase of 1,680,633 is due to the share premium account of 1,680,633 and the decrease of 1,680,633 is due to the share premium account of 1,680,633. The amount for the decrease in the share premium of capital surplus is 27,438,582. This has been recorded in the Profit and Loss account and the consolidated statement of financial position of 31 December 2020.

The amount for the increase in the share premium of capital surplus is 16,710,203. This is due to the share-based payments of 16,710,203 recorded in the Profit and Loss account and the consolidated statement of financial position of 31 December 2020. The amount for the decrease in the share premium of capital surplus is 0,000,000. This is due to the share-based payments of 16,710,203 recorded in the Profit and Loss account and the consolidated statement of financial position of 31 December 2020. The amount for the decrease in the share premium of capital surplus is 0,000,000. This is due to the share-based payments of 16,710,203 recorded in the Profit and Loss account and the consolidated statement of financial position of 31 December 2020.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Reserves and provisions (continued)

(32) Surplus reserve

	31 December 2019	Appropriation 2020	Decrease 2020	31 December 2020
Surplus reserve	33,183,321	3,034,088		36,593,229

The account is the result of the allocation of the profit of the year, the profit is appropriated 10% of the profit for the year ended 31 December, the profit is appropriated to the surplus reserve account and 10% of the retained earnings is appropriated to the surplus reserve account for the year ended 31 December 2020.

(33) Retained earnings

2020 2019

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Revenue and cost of sales (continued)

(34) Revenue and cost of sales

	2020	
	Revenue	Cost
Submarine	978,466,160	701,039,798
Other	52,817,600	27,662,054
	1,031,283,760	728,701,852

	2019	
	Revenue	Cost
Submarine	73,483,663	616,183,633
Other	67,000,666	4,000,311
	80,484,329	656,184,564

(a) Revenue and cost of sales from Submarine

	2020	
	Revenue	Cost
License income	222,586,930	194,543,819
Revenue from engineering services	755,879,230	506,495,979
	978,466,160	701,039,798

	2019	
	Revenue	Cost
License income	5,615,871	174,378,815
Revenue from engineering services	587,873,722	441,785,818
	73,484,329	656,184,564

(i) Revenue and cost of sales from license income and revenue from engineering services in revenue and cost of sales

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4 Notes to the consolidated financial statements (continued)

(36) Expenses by nature

The following table sets out the nature of expenses, categorized by nature of expense, and the amount of each category of expense for the year ended 31 December 2020 and 2019:

	2020	2019
Employee benefits	339,081,062	288,688,273
Financial and non-financial costs	260,283,959	220,125,566
Depreciation	3,339,117	28,684,808
- of fixed assets	41,037,075	34,070,488
- of intangible assets	33,116,519	1,851,521
Amortization of intangible assets	14,101,748	0,874,756
Amortization of deferred expense	35,549,405	34,866,665
(Costs of operations) and other expenses	4,382,432	2,350,000
- other expenses	44,513,962	35,041,616
- other	19,138,805	18,580,005
- other	14,146,526	16,080,411
- fee	24,081,462	17,325,000
- other	6,622,267	2,442,633
Administrative expenses		
- Administrative	800,000	2,000,000
- other	24,500	26,000
- other	2,914,695	3,335,565
- other	4,170,744	6,242,376
- other	5,256,718	5,820,433
Share-based payments (cost)	5,887,603	5,526,000
Other	24,360,545	16,688,000
	882,809,144	733,511,000

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

4. Financial expenses – net (continued)

(37) Financial expenses – net

	2020	2019
Balance at the beginning	20,173,820	17,231,667
18,820,000 (1,350,000) (1,851,718) (1,041,380) (1,851,718) (1,041,380) (1,851,718) (1,041,380) (1,851,718) (1,041,380)		

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in BHKD unless otherwise stated)

4. Other non-current assets and liabilities (continued)

(40) Gains from changes in fair value

	2020	2019
Value of properties held for sale (note 4)	476,174	1,099,16
Realised gains from disposal of properties held for sale (note 4(8))	6,123,049	87,546
	6,599,223	19,174,62

(41) Credit impairment losses

	2020	2019
Losses on balances of accounts receivable	23,341,488	19,356,414
Losses on balances of other receivables	(215,732)	8,899,0
Total	23,125,756	28,256,324

(42) Assets impairment losses

	2020	2019
Goodwill impairment	8,011,603	

(43) Non-operating income

	2020	2019
Other income	59,275	2,750,43
Share of the economic profit of companies in which the Group has an interest	-	25,666,158
Income	849,765	2,67,326
	909,040	28,388,527

Notes to the Financial Statements

For the year ended 31 October 2020
 (As approved by the Board of Directors)

4 Non-operating income and expenses (continued)

(44) Non-operating expenses

	2020	2019
Administrative	8,537,428	2,87,277
Technical and professional	1,518,692	10,55,300
Provision of employee benefits	-	8,418,374
Provision of contingencies	-	4,822,111
Other items (net of 28)	-	2,00,000
Total	845,825	4,43,062
	10,901,945	1,71,30,68

(45) Income tax expenses

	2020	2019
Income tax expense based on taxable income	31,485,064	23,40,066
Deferred income tax	(2,536,393)	(6,113,877)
Total	28,948,671	17,28,189

The reconciliation of income tax expense based on the applicable rate of 25% on profit before income tax to income tax expense is as follows:

	2020	2019
Profit	87,904,215	55,522,077
Income tax expense at applicable rate of 25%	21,976,054	13,880,519
Effect of tax benefits	(391,588)	-
Losses, expenses and other items before tax	4,889,834	2,741,475
Rate difference for prior periods	(1,722,889)	-
Adjustment of effect of each of the employee benefits	(2,071,323)	(10,3,408)
Effect of one of the non-deductible expenses	10,127,644	8,337,400
Adjustment of effect of one of the non-deductible expenses	(3,859,061)	-
Provision of effect of one of the non-deductible expenses	-	(6,624,000)
Income tax expense	28,948,671	17,28,189

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4. Environmental performance indicators (continued)

(46) Earnings per share

(a) Basic earnings per share

	2020	2019
Profit attributable to ordinary shareholders of parent company (B\$ million)	70,000,134	57,283,334
Dividends payable to ordinary shareholders of parent company (B\$ million) (i)	72,452,438	73,000,000
Basic earnings per share (B\$)	0.97	0.78

(i) At the end of the year, for the purpose of calculating the weighted average number of 13.7 million shares, the dividend in the amount of 72,452,438 B\$ million was included in the calculation. At the end of the year, the dividend payable to ordinary shareholders, according to the period of Account Settlement for Business Enterprise of 71.5% of the total of 100,000,000 shares, the dividend in the amount of 72,452,438 B\$ million was included in the calculation of basic earnings per share of 0.97 B\$. The dividend payable to ordinary shareholders of 73,000,000 B\$ million was included in the calculation of basic earnings per share of 0.78 B\$.

(b) Diluted earnings per share

Diluted earnings per share is calculated based on profit attributable to ordinary shareholders of parent company adjusted by the potential ordinary shares which are convertible into ordinary shares. For the year ended 31 December 2020, the profit attributable to ordinary shareholders of parent company adjusted by the potential ordinary shares was B\$70,000,134. The adjusted dividend payable to ordinary shareholders was 72,824,553. The diluted earnings per share was B\$ 0.6. For the year ended 31 December 2019, the profit attributable to ordinary shareholders of parent company adjusted by the potential ordinary shares was B\$57,283,334. The adjusted dividend payable to ordinary shareholders was 73,270,666. The diluted earnings per share was B\$ 0.77.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Supplementary information to the cash flow statement (continued)

(47) Supplementary information to the cash flow statement

(a) Supplementary information to cash flow statement
excluding from the profit or loss for operational activities

	2020	2019
Profit	58,955,544	38,227,618
Adjusted Profit	8,011,603	
Adjusted Profit	23,125,756	2,256,324
Provision of the fuel	41,037,075	34,070,48
Provision of the off-gas	33,116,519	2,85,521
Provision of the libe	14,101,748	0,874,756
Provision of the prepa	35,549,405	34,8,665
(Loss)/Gain of the fuel, the libe and the off-gas	(692,250)	(3,585,518)
Provision of the fuel	(6,599,223)	(1,17,462)
Provision of the fuel of the fuel of the fuel		(25,666,158)
Loss of the fuel of the prepa of the fuel		13,20,43
Provision of the fuel	26,805,140	27,18,834
Provision of the fuel	7,665,311	(24,336,266)
Share-based payment	5,887,603	5,0,526
Provision of the fuel	(303,792)	(0,3,72)
Provision of the fuel	305,286	(5,02,876)
Provision of the fuel	(2,841,679)	(61,001)
Provision of the fuel	(12,896,656)	(1,630,53)
Provision of the fuel	(19,356,716)	(24,652,0)
Provision of the fuel	(12,214,682)	(24,124,74)
Cash flow for operational activities	199,655,992	111,28,775

Notes to the Financial Statements

For the year ended 31 October 2020
(As approved by the Board of Directors)

4 Supplementary information to the cash flow statement (continued)

(47) Supplementary information to the cash flow statement (continued)

(a) Significant non-cash transactions (continued)

Significant non-cash transactions in relation to the acquisition of the subsidiary.

For the year ended 31 October 2020, significant non-cash transactions in relation to the acquisition of the subsidiary are as follows:

	2020	2019
involvement in the acquisition of the subsidiary (Note 4(12))	33,603,772	234,634,171
	2020	2019
acquisition of the equity	200,092,665	164,514,000
less: acquisition of the equity	(164,951,950)	(187,666,644)
net cash/(receipt) in cash	35,140,715	

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

4 Supplementary information to the cash flow statement (continued)

(47) Supplementary information to the cash flow statement (continued)

(c) Reconciliation of the change of balance sheet items

	2020
Assets	2,653,61
Off-balance sheet	45,528,15
Liabilities	(25,888,6)
Off-balance sheet	(6,70,000)

(*) Reconciliation of

	31 December 2020	31 December 2019
Assets		
Balance sheet	374,287	45,334
Off-balance sheet		
Balance sheet	199,718,378	164,33,34
Off-balance sheet	-	1,3,222
Total assets	200,092,665	164,51,0

Notes to the Financial Statements

For the year ended 31st October 2018
(As approved by the Board of Directors)

5. Environmental liabilities scope

The environmental liabilities of the E-Logica (India) Co., Ltd. are payable to the Environmental Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000.

The Environmental Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, is payable to the Environmental Co. of Rs. 50,00,000.

As per the terms of the E-Logica (India) Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, of which Rs. 50,00,000 is payable to the Environmental Co. of Rs. 50,00,000.

As per the terms of the E-Logica (India) Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, of which Rs. 50,00,000 is payable to the Environmental Co. of Rs. 50,00,000. As per the terms of the E-Logica (India) Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, of which Rs. 50,00,000 is payable to the Environmental Co. of Rs. 50,00,000. As per the terms of the E-Logica (India) Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, of which Rs. 50,00,000 is payable to the Environmental Co. of Rs. 50,00,000.

The Environmental Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, is payable to the Environmental Co. of Rs. 50,00,000. As per the terms of the E-Logica (India) Co., Ltd. (→ E-Logica (India) (Environmental Co.)) of Rs. 50,00,000, of which Rs. 50,00,000 is payable to the Environmental Co. of Rs. 50,00,000.

Notes to the Financial Statements

For the year ended 31 December 2020
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

5 Business combination involving enterprises not under common control

(1) Business combination involving enterprises not under common control

(a) Business combinations involving enterprises not under common control

Acquiree	Date of acquisition	Purchase consideration	% of equity interest	Date of purchase	Basis for determination of date of acquisition	Revenue of the acquiree from the date of purchase to the end of the year	Net profit of the acquiree from the date of purchase to the end of the year	Cash flows from operating activities of the acquiree	
								from the date of purchase to the end of the year	from the date of purchase to the end of the year
Company A	31 Dec 2020	8,000,000	53.33%	31 Dec 2020	Acquired	18,62,736	1,257,371	(12,786,80)	1,425,47
Company B	31 Aug 2020	12,51,03	100%	31 Aug 2020	Acquired	7,827,31	2,474,43	(227,3)	1,321,53

(b) Business combinations involving enterprises not under common control

	2020	2019
	(RMB)	(RMB)
Business combinations		
Cost of acquisition	8,000,000	
Less: fair value of net assets acquired (see 4(13))		12,51,03
Goodwill	8,000,000	12,51,03
Less: Share of fair value of identifiable intangible assets acquired	(18,177,0)	4,635
Goodwill	11,822,0	13,448,538

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

5 Business combination scope (continued)

(1) Business combination involving enterprises not under common control (continued)

(c) Details of identifiable intangible assets of purchase price difference as follows:

(i) Intangible assets

	Balance at the beginning of the year	Change of purchase price	Balance at the end of the year
Amortizable intangible assets	4,066,40	4,066,40	7,803,25
Non-amortizable	60,310,47	60,310,47	40,024,44
Trade names	842,56	842,56	1,100,38
Patents			31,483
Human resources	2,250,67	2,250,67	2,356,833
Other intangible assets	27,514,3	514,3	576,46
Long-term prepaid expenses	3,068,67	3,068,67	3,037,57
Prepaid expenses	325,06	325,06	1,354
Deferred expenses	66,177	66,177	
Prepaid expenses	(36,82)	(36,82)	(3,01,277)
Accounts payable	(2,557,7))	(2,557,7))	(3,614,442)
Other liabilities	(442,48)	(442,48)	(470,35)
Employee benefit payable	(42,30)	(42,30)	(581,572)
Other liabilities	(2,873)	(2,873)	(310,82)
Deferred liabilities	(6,70,000)		
Net amount	340,83,715	13,833,715	11,030,5
Less: non-controlling interest	(15,05,745)	(6,456,15)	(5,228,76)
Net amount attributable	18,177,0	7,377,50	5,743,36

The scope of identifiable intangible assets of intangible assets (patents, trade names of purchase price difference) were determined according to the scope of the identifiable intangible assets:

The acquisition approach of the intangible assets is the acquisition approach. The scope of the intangible assets includes the intangible assets that are not paid for in the operation, are not paid for in the purchase price, and are not paid for in the purchase price.

Notes to the Financial Statements

For the year ended 31 December 2020
(A B e o e i e e e)

5 e i e c o i i o e (c o i e)

(1) Business combination involving enterprises not under common control (c o i e)

Notes to the Financial Statements

For the year ended 31 December 2023
(All amounts in BHKD unless otherwise stated)

6. Related parties

(1) Interest in subsidiaries

(a) Significant

Name of the subsidiaries/units	Type of entity	Major business location
--------------------------------	----------------	-------------------------

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

6 Investment in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(a) Significant subsidiaries (continued)

Name of the subsidiaries/units	Type of entity	Major business location	Place of registration	Nature of business	Shareholding (%) as at 31 December 2020		Method of acquisition
					Direct	Indirect	
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		75.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		51.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		51.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		60.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		51.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		65.38 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		51.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		64.55 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		65.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		53.33 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired
Electra (SI) PLC	LLC	Sierra Leone	Sierra Leone	Electricity		00.00 %	Acquired

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

6 Investment in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(b) Non-controlling interest

	31 December 2020	31 December 2019
Local subsidiary	19,893,809	
Overseas subsidiary	7,703,174	8,465,006
Shareholding of non-controlling interest	6,994,726	11,640,006
Shareholding of non-controlling interest in subsidiaries	15,159,737	14,224,263
Shareholding of non-controlling interest in subsidiaries	11,764,309	0,000,000
Shareholding of non-controlling interest in subsidiaries	9,845,907	10,554,777
Shareholding of non-controlling interest in subsidiaries	11,262,400	12,660,664
Total	19,954,480	22,884,371
Total	102,578,542	97,242,255

(c) Subsidiaries in which non-controlling interest

Name of subsidiaries	Shareholding of non-controlling shareholders (%)	Profit or loss attributed to non-controlling shareholders as at 31 December 2020	Dividends distributed to non-controlling shareholder as at 31 December 2020	Non-controlling interests as at 31 December 2020
Local subsidiary	40%	(106,191)	-	19,893,809
Shareholding of non-controlling interest in subsidiaries	25%	935,474	-	15,159,737
Shareholding of non-controlling interest in subsidiaries	34%	783,971	-	11,764,309
Shareholding of non-controlling interest in subsidiaries	49%	(1,403,664)	-	11,262,400
		209,590	-	58,080,255

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B Maldivian Rufiyaa)

6 Investment in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(c) Subsidiary in dividend non-current investments (continued)

The following table provides a breakdown of dividend non-current investments of the company as follows:

	31 December 2020					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities
Local companies	11,379,262	41,840,261	53,219,523	3,485,000	-	3,485,000
Electra (S) P. Ltd.	11,872,301	133,946,018	145,818,319	77,661,341	7,518,031	85,179,372
Electra (S) P. Ltd.	33,174,567	18,979,615	52,154,182	17,553,274	-	17,553,274
Local companies	15,275,548	36,143,566	51,419,114	18,756,949	9,677,675	28,434,624
	71,701,678	230,909,460	302,611,138	117,456,564	17,195,706	134,652,270

	2020			
	Revenue	Net (loss)/profit	Total comprehensive (losses)/income	Cash flows from operating activities
Local companies	-	(265,477)	(265,477)	5,014,560
Electra (S) P. Ltd.	11,033,761	3,741,896	3,741,896	5,826,841
Electra (S) P. Ltd.	4,214,044	2,305,796	2,305,796	7,499,276
Local companies	13,882,909	(2,864,620)	(2,864,620)	(1,705,998)
	29,130,714	2,917,595	2,917,595	16,634,679

Notes to the Financial Statements

For the year ended 31 October 2014
(As approved by the Board of Directors)

6 Investment in subsidiaries (continued)

(1) Interest in subsidiaries (continued)

(c) Subsidiaries in which the Group has a controlling interest (continued)

The following table shows the Group's interest in subsidiaries in which the Group has a controlling interest as at 31 October 2014:

	31 October 2014					
	Group shareholding	Group shareholding	Group shareholding	Group shareholding	Group shareholding	Group shareholding
Group shareholding	0,723,571	136,658,70	147,382,271	0,774,533	0,70,646	0,485,23
Subsidiaries (Group shareholding)	0,00,652	5,857,08	0,158,30	6,661,70	37,80,155	44,511,875
Jointly controlled entities	42,47,41	0,525,52	51,023,533	21,84,521		21,84,521
Associate companies	11,360,13	3,83,413	51,25,426	15,228,18	0,182,114	25,40,312
Banking companies	180,2,778	38,00,41	56,88,81	2,42,71	21,63,741	24,132,50
Finance companies	6,75,714	86,10,36	0,280,10	17,438,226	66,53,532	84,31,758
	0,50,66	30,871,80	40,412,53	144,440,57	145,76,188	0,421,245

(2)

	Group's interest in subsidiaries			
	Group shareholding	Group shareholding	Group shareholding	Group shareholding
Group shareholding	3,418,154	2,447,81	2,447,81	27,03,527
Subsidiaries (Group shareholding)	14,527,80	(11,424,25)	(11,424,25)	(8,70,268)
Jointly controlled entities	3,89,018	(100,058)	(100,058)	3,842,343
Associate companies	14,644,462	(3,263,285)	(3,263,285)	4,311,374
Banking companies	160,44,22	(4,08,10)	(4,08,10)	(184,41)
Finance companies				

Notes to the Financial Statements

For the year ended 31 December 2020
 (Audited by the Big 4 Certified Public Accountants)

6 Interests in associates (continued)

(2) Interests in associates

(a) Significant associates of significant nature

	Major business location	Place of registration	Nature of business	Whether strategic to the Group's activities	Shareholding (%)	
					Direct	Indirect
Hangzhou Anken Information Technology	Hangzhou	Hangzhou	Information technology	0	4	
Chengdu Yining Hospital	Chengdu	Chengdu	Medical service	0	24	
Shanxi Shanda	Shanxi	Shanxi	Medical service	0	9	

Information on the associates is given in the notes to the financial statements.

(b) Significant associates of significant nature

	31 December 2020 Hangzhou Anken Information Technology	31 December 2020 Chengdu Yining Hospital	31 December 2020 Shanxi Shanda
Assets	21,843,683	14,877,237	27,742,224
Liabilities	19,898,732	53,502,689	63,554,292
Equity	41,742,415	68,379,926	91,296,516
Equity attributable to owners of the reporting entity	27,809,556	33,451,286	70,269,011
Share of the associate's equity (i)	8,055,177	8,028,309	21,080,703
Adjustment to equity	-	5,024,000	4,494,286
Equity	4,500,000	99,975	-

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in RMB unless otherwise specified)

6 Investments in associates (continued)

(2) Interests in associates (continued)

(b) Significant associates of the Group (continued)

	2020	2020	2020
	Hangzhou Anken Information Technology	Chengdu Yining Hospital	Shanxi Shanda
Carrying amount	37,414,435	10,078,842	19,503,386
Goodwill	(14,409,474)	(3,877,172)	1,491,929

(i) The carrying amount of the investments in associates is based on the proportion of the Group's shareholding in the associates' net assets. The carrying amount of the investments in associates is based on the effective interest method. The carrying amount of the investments in associates is based on the effective interest method. The carrying amount of the investments in associates is based on the effective interest method.

(c) Significant associates of the Group

The carrying amount of the investments in associates is as follows:

	2020	2019
Carrying amount of investments	42,444,061	50,732,373
Carrying amount of investments in proportion	(2,841,799)	(2,841,799)
Goodwill	(2,841,799)	(2,841,799)

(i) The carrying amount of the investments in associates is based on the effective interest method. The carrying amount of the investments in associates is based on the effective interest method.

7 Significant associates

The significant associates of the Group are the business units of the Group's subsidiaries, or operating units of the Group's subsidiaries, or the business units of the Group's subsidiaries. The significant associates of the Group are the business units of the Group's subsidiaries, or the business units of the Group's subsidiaries, or the business units of the Group's subsidiaries.

As at 31 December 2020, the significant associates of the Group are as follows:

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

8 Related party transactions (continued)

(4) Related party transactions

(a) Goods sold

The price of goods sold to related parties is determined based on the market price.

(b) Portfolio of receivables due to related parties

	2020	2019
Trade receivables	3,000,000	3,000,000
Other receivables	629,767	572,743
	3,629,767	3,572,743

(c) Lease

The following table summarizes the lease liabilities to related parties:

Year of lease	Period of lease	2020	2019
12 months	12 months	-	6,652,400

The lease liabilities are reported as follows to related parties:

	2020	2019
12 months	299,117	6,652,372

(d) Liabilities due to related parties

	2020	2019
Provision of financial liability to related parties	3,360	-
Other liabilities (operating)	514,369	2,022,700
Interest	-	10,412
	517,729	2,033,112

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

8 Related party transactions (continued)

(4) Related party transactions (continued)

(e) Advances paid to related parties

	2020	2019
€ million	2,726,131	

(f) Expenses incurred by related parties

	2020	2019
€ million		
Expenses incurred by related parties	-	15,274,000
Expenses incurred by related parties	-	2,800,000
	-	180,740,000

(g) Expenses incurred by related parties

	2020	2019
€ million	4,000,000	

(h) Share-based payments

	2020	2019
€ million		
Share-based payments	5,041,695	4,500,000
Share-based payments	490,634	453,432
	5,532,329	4,953,432

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

8 Related parties and related party transactions (continued)

(4) Related party transactions (continued)

(i) Acceptance of subscription deposits

	2020	2019
Subscription deposits	18,000,000	
Subscription deposits / deposits	280,000,000	30,000,000
Subscription deposits / deposits / interest	50,000,000	
Deposits / Subscription deposits	2,500,000	
Deposits / Subscription deposits / interest	75,000,000	2,000,000
Others	992,970	
	426,492,970	30,000,000

(j) Increase of share

	2020	2019
Share premium	-	1,012,78

Refer to the related party transactions of the share premium, increase of share premium.

(k) Balance of share premium

	2020	2019
Share Premium	-	1,012,78

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

8 Receivables and payables (continued)

(5) Receivables from and payables to related parties (continued)

(b) Trade receivables

		31 December 2020	31 December 2019
Trade receivables	Set-off	-	1,000
	Other	-	80,000
		-	2,20,000
Trade payables	(Set-off)	-	15,000
	Other	4,074,900	4,232,754
	(Set-off)	-	1,019,500
	Set-off	5,844,383	3,412,644
	Other	-	40,000
	Other	2,917,717	-
	Other	-	2,80,000
	Other	23,252	241,185
	Other	9,989	2,866
		12,870,241	28,41,713
Lease liability	Other	5,665,172	6,754,366

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

8 Financial performance of the company (continued)

(6) Equity and interest of directors

(a) Board of Directors and Chief Executive

2020, the Board of Directors, the Chief Executive and the Board:

Name	Emoluments	Contributions				Total
		Salaries and subsidies	to pension plans	Bonus	Other welfare	
Executive directors (i)						
Chairman	-	398,454	18,205	89,291	34,180	540,130
Director	-	326,454	-	128,611	28,212	483,277
Director	-	184,330	8,335	105,865	41,798	340,328
Non-executive directors (i)						
Director	-	-	-	-	-	-
Director	-	-	-	-	-	-
Independent directors						
Director	35,000	-	-	-	-	35,000
Director	35,000	-	-	-	-	35,000
Director	35,000	-	-	-	-	35,000
Director	35,000	-	-	-	-	35,000
Director	35,000	-	-	-	-	35,000
Director	35,000	-	-	-	-	35,000
Supervisors						
Supervisor	-	-	-	-	-	-
Supervisor	-	71,074	8,722	68,526	17,723	166,045
Supervisor	-	-	-	-	-	-
Supervisor	-	-	-	-	-	-
Supervisor	-	-	-	-	-	-
Total	210,000	980,312	35,262	392,293	121,913	1,739,780

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

8 Share premium and share reserve (continued)

(6) Equity and interest of directors (continued)

(a) Director's office (continued)

2020, Director's office, Director's office (continued)

	Share	Director's office	Director's office	Director's office	Director's office
2020	Director's office	Director's office	Director's office	Director's office	Director's office

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

8 General and special dividends (continued)

(6) Equity and interest of directors (continued)

(a) Provision of director and other services (continued)

	Provision of director service to the Company or the subsidiaries	2020 Provision of other services to the Company or the subsidiaries	Total
Provision of director services	–	1,363,735	1,363,735

	2019 Provision of director service to the Company or the subsidiaries	2019 Provision of other services to the Company or the subsidiaries	Total
Provision of director services	1,177,840	1,177,840	2,355,680

(i) The remuneration of the directors of the Company


is set out in Note 10 to the financial statements, etc.

(7) The five individuals whose emoluments were the highest

The five individuals whose emoluments were the highest for the year ended 31 December 2020 (Note 10(i)) are the directors whose names are set out in the table below (Note 10(i) hereafter):

	2020	2019
Basic salary, bonus, commission and other benefits	4,449,720	3,744,211
Emoluments in kind	305,924	152,553
	4,755,644	3,896,764

		Headcount	
		2020	2019
Age:			
B50 000	B100 000	3	5
B100 000	B1,50 000	2	–
		5	5



Notes to the Financial Statements

For the year ended 31 December 2020
(Annual Report and Business Review 2020)

13 Financial risks

The Group is exposed to a range of financial risks: market risk (primarily foreign exchange rates and interest rates), credit risk and liquidity risk. The Group's overall risk management policy focuses on the applicability of financial instruments to the potential adverse effect of the Group's financial performance.

(1) Market risk

(a) Foreign exchange risk

The Group's major operations are carried out in and through major subsidiaries of the Group located in the People's Republic of China. The Group is exposed to foreign exchange risk for the economic and financial performance of the Group's operations in the United States ("US"). The Group's major operations are carried out in the People's Republic of China, and the majority of the Group's assets, liabilities and operations are denominated in the local currency, the Chinese Renminbi ("RMB").

As at 31 December 2020 and 31 December 2019, the Group's major subsidiaries of the Group are located in the United States and the local currency is the US Dollar ("USD").

	31 December 2020		Total
	HKD	USD	
Financial assets and liabilities	69,340	2,109,936	2,179,276
	31 December 2019		
		USD	
Financial assets and liabilities	3,333,874	8,143,811	11,477,685

As at 31 December 2020, the Group's major subsidiaries of the Group in the United States, if the US Dollar/ Renminbi exchange rate is 3% higher or lower than the current rate, the Group's profit for the year would be approximately HK\$34 (31 December 2019: HK\$258,231) more or less, respectively.

Notes to the Financial Statements

For the year ended 31 December 2023
(As approved by the Board of Directors)

13 Financial risks (continued)

(2) Credit risk (continued)

The creditable receivables are analysed by type of receivable, by product type, by region for the product and by industry. The credit risk of receivables is evaluated by the age of receivables and the non-accrual risk. The maximum amount of receivables of the creditable receivables is analysed by type of receivable.

For the receivables are the type of product, project, company and by type of receivable non-accrual risk.

(3) Liquidity risk

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

13 Financial Instruments (continued)

(3) Liquidity risk (continued)

Bank borrowings and other borrowings are classified by expected maturity as follows:

	31 December 2020		31 December 2019	
	Bank borrowings	Other borrowings	Bank borrowings	Other borrowings
Less than 1 year	315,500,000	-	40,000,000	17,400,000
1-2 years	15,992,970	-	3,000,000	2,200,000
2-5 years	64,000,000	-	1,700,000	-
More than 5 years	31,000,000	-	-	-
	426,492,970	-	45,000,000	19,600,000

14 Financial Instruments

The following table details the financial instruments held by the Group as at the reporting date, classified by their maturity:

Level 1: Quoted prices (unadjusted) in active markets for identical liabilities.

Level 2: Quoted prices in active markets for similar liabilities, or quoted prices for identical liabilities in markets that are not active, or other observable inputs.

Level 3: Unobservable inputs for liabilities.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

14 Fair value measurement (continued)

(1) Assets measured at fair value on a recurring basis

At 31 December 2020 and 31 December 2019, the following table sets out the fair value measurement of the assets measured at fair value on a recurring basis:

	31 December 2020		
	Level 1	Level 2	Level 3
Intangible assets -			
- other intangible assets	-	-	57,404,918
- intangible assets			
- other properties	-	-	107,804,936
- other	-	-	165,209,854
	31 December 2019		
	Level 1	Level 2	Level 3
Intangible assets			
- Intangible assets for sale		9,000,000	
- other intangible assets			51,281,866
- intangible assets			
- other properties			10,856,000
- other		9,000,000	162,137,600

For other intangible assets, the appropriate measurement basis of the fair value of the assets is determined as follows:

For properties that are held for sale, the appropriate measurement basis of the other properties is the fair value less costs to sell. For other properties held for sale, the appropriate measurement basis/capitalized amount is the carrying amount less the loss recognized in accordance with section 28(a)(iii) of the Act.

The intangible assets of the company are held for sale only in the case of intangible assets that are intangible liabilities. These intangible assets are held for sale as a result of the sale of the company's other properties. The above amounts represent the carrying amount of the intangible assets of the company, which are held for sale, and are not adjusted for the carrying amount of the other properties.

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

14 Fair value measurement (continued)

(2) Assets and liabilities not measured at fair value but disclosed

Financial assets and liabilities measured at fair value are not measured at fair value but disclosed, payable, derivative payable, bond payable, etc.

The difference between the carrying amount of financial assets and liabilities and their fair value is not material.

15 Capital management

The objective of capital management is to provide the opportunity for the company to continue to grow and to create value for its shareholders and to ensure the company's ability to meet its financial obligations, and to ensure the company's ability to continue to create value for its shareholders.

The company's capital management strategy is to ensure that the company has sufficient capital to meet its financial obligations, and to ensure the company's ability to continue to create value for its shareholders.

The company's capital management strategy is to ensure that the company has sufficient capital to meet its financial obligations, and to ensure the company's ability to continue to create value for its shareholders.

As at 31 December 2020 and 31 December 2019, the company's capital management ratios are as follows:

	31 December 2020	31 December 2019
Capital ratio	41.55%	42.42%



Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors on 18 February 2021)

16 Notes to the consolidated financial statements

(1) Accounts receivable

	31 December 2020	31 December 2019
Accounts receivable	89,073,254	102,378,543
Less: provision for bad debts	(10,529,013)	(10,173,228)
	78,544,241	92,205,315

Accounts receivable are reported at their net realizable value.

(a) Breakdown of accounts receivable based on the economic risk transfer date as follows:

	31 December 2020	31 December 2019
within 1 year	65,324,295	81,489,131
1-2 years	15,285,769	23,570,877
2-3 years	8,461,922	4,748,652
over 3 years	1,268	10,811
	89,073,254	110,819,471

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

16 Notes on accounts receivable and other receivables (continued)

(1) Accounts receivable (continued)

(b) Provision for bad debts

The provision for the impairment of accounts receivable and other receivables is determined on the basis of the expected credit losses, and is based on the expected credit losses on the receivables.

At 31 December 2020, the expected credit losses for the provision for bad debts and provision for impairment are as follows: (31 December 2019: B1,883,254).

(i) Accounts receivable and other receivables provision for bad debts and provision for impairment are as follows:

	31 December 2020			31 December 2019		
	Book value	Provision for bad debts		Book value	Provision for bad debts	
	Amount	Lifetime ECL rate	Amount	Amount	Lifetime ECL rate	Amount
Government bonds	7,317,813	1%	73,178	9,440,38	1%	9,440
Financial institutions	38,694,940	4%	1,547,798	45,722,87	5%	2,286,14
Individuals	19,311,542	4%	772,462	25,455,551	6%	1,547,733
12 months	15,285,769	20%	3,057,154	23,164,463	11%	2,551,611
13 months	8,461,922	60%	5,077,153	3,622,35	0%	1,811,10
13 months	1,268	100%	1,268	0,81	00%	0,81
Total	89,073,254		10,529,013	107,448,288		8,283,74

(ii) The amount of provision for bad debts and provision for impairment are B7,312,656 in the provision for bad debts and impairment.

(iii) The balance of accounts receivable and other receivables is B6,56,871, and the provision for bad debts is B6,56,871, which is equal to the amount of 12 months.

The impairment of accounts receivable and other receivables is determined on the basis of the expected credit losses.

Notes to the Financial Statements

For the year ended 31 December 2020
(Amounts in thousands of Euros)

16 Other receivables (continued)

(2) Other receivables

	31 December 2020	31 December 2019
Trade receivables	518,639,070	500,614,238
Advance	4,671,223	11,524,615
Prepaid expenses	859,992	1,548,836
Other	609,392	1,077,033
	524,779,677	574,764,722
Less: Provision for bad debts	(3,105,773)	(1,044,481)
	521,673,904	564,146,033

(a) Breakdown of trade receivables by age group:

	31 December 2020	31 December 2019
0-12 months	276,741,017	215,775,738
13-30 months	88,671,969	243,448,245
31-60 months	147,314,919	108,745,871
Over 60 months	12,051,772	6,221,238
	524,779,677	574,191,092

(b) Provision for doubtful receivables

Notes to the Financial Statements

For the year ended 31 December 2022
(As approved by the Board of Directors)

16 Other receivables and prepaid expenses (continued)

(2) Other receivables (continued)

(b) Provision for impairment losses on book value (continued)

(i) As at 31 December 2022, for other receivables under Sale 1, the impairment provision for bad debts is as follows:

	Book value	12-month ECL rate	Provision for bad debts
Provision for impairment losses:			
Advance	2,515,108	7%	176,058
receivable from lease payable on the date of sale	23,987,265	5%	1,199,363
receivable from lease payable on the date of sale (i)	494,651,805	-	-
provision for advance	859,992	3%	25,800
others	609,392	1%	6,094
	522,623,562		1,407,315

(i) Due to the high volatility of the real estate market, the credit condition of the counterparty of the receivable from lease payable on the date of sale is highly uncertain. In view of the receivable from lease payable on the date of sale, the provision for the impairment loss of receivable from lease payable on the date of sale is as follows:

(ii) As at 31 December 2022, the provision for impairment losses on other receivables under Sale 2:

(iii) As at 31 December 2022, for other receivables under Sale 3, the impairment provision for bad debts is as follows:

	Book value	Lifetime ECL rate	Provision for bad debts
Provision for impairment losses:			
receivable from lease payable (see 4(3)(b)(iii))	2,156,115	79%	1,698,458
	2,156,115		1,698,458

(c) 2022, other receivables of B7,114,170 are listed off balance sheet.

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

16 Long-term equity investment (continued)

(3) Long-term equity investment

	31 December 2020	31 December 2019
Subsidiary (a)	420,377,432	Ø 5,477,432
Associate (b)	33,465,928	32,151,227
	453,843,360	337,636,659

The following table provides a breakdown of the long-term equity investment by subsidiary.

(a) Subsidiary

	31 December 2019	Additional investment for the year ended 31 December 2020	Disposal for the year ended 31 December 2020	31 December 2020
Energy Services (opco)	32,000,000			32,000,000
Energy Services (opco)	20,000,000			20,000,000
Energy Services (opco)	27,400,000	9,750,000		37,150,000
Energy Services (opco)	1,000,000			1,000,000
Energy Services (opco)	500,000			500,000
Energy Services (opco)	10,000,000			10,000,000
Energy Services (opco)	1,600,000			1,600,000
Energy Services (opco)	Ø 900,000	847,000	-	(Ø 847,000)
Energy Services (opco), Ltd.	34,627,432			34,627,432
Energy Services (opco)	168,000,000	31,000,000		200,000,000
Energy Services (opco)		Ø 30,000,000		30,000,000
Energy Services (opco)		53,000,000		53,500,000
	Ø 5,477,432	125,747,000		420,377,432
			(Ø 847,000)	420,377,432

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B Maldivian Rufiyaa)

16 Non-current assets (continued)

(3) Long-term equity investment (continued)

(b) Analysis

	31 December 2019	Value added	Decrease in value	Share of profit/(loss) for the year ended	31 December 2020	Goodwill added of the year
Share in Associated Companies						
Equity	5,368,006	0,000,000		(4,022,78)	10,965,928	
Share in Associated Companies	26,710,21		(23,34,663)	(3,756,358)	-	
Goodwill		22,00,000			22,500,000	
	32,15,227	32,00,000	(23,34,663)	(8,158,636)	33,465,928	

(4) Fixed assets

	Buildings	Medical equipment	Motor vehicles	Electronic and other equipment	Total
Cost					
31 December 2019	326,10,267	37,367,314	3,10,636	18,431,52	380,5,746
Increase	17,06,46	7,02,642	173,42	1,30,311	26,43,841
Disposals/Retirement		(588,78)	(30,5)	(1,3,861)	(2,868,88)
Decrease (0.40%)	(1,82,787)				(1,82,787)
31 December 2020	324,117,426	43,881,878	2,983,619	17,801,979	388,784,902
Accumulated Depreciation					
31 December 2019	30,53,353	23,366,00	2,382,08	11,26,727	74,7,488
Goodwill	2,114,133	5,05,432	180,66	2,721,543	17,53,174
Disposals/Retirement		(576,38)	(323,11)	(1,844,854)	(2,745,154)
31 December 2020	46,167,486	28,295,943	2,256,663	12,873,416	89,593,508
Net Book Value					
31 December 2020	277,949,940	15,585,935	726,956	4,928,563	299,191,394
31 December 2019	280,56,14	14,00,414	768,128	6,434,02	30,20,258

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B Mauritian Rupees)

16 Intangible assets (continued)

(4) Fixed assets (continued)

The expenditure of the year ended 31 December 2020 was B17,533,174 (2019: B17,115,400), which includes the acquisition of computer software, the acquisition of intangible assets, the acquisition of licences and the acquisition of other intangible assets. The expenditure for the year ended 31 December 2019 was B14,873,361, of which B300,520, B4,887 and B225,740 respectively (2018: B13,742,443, B3,370,640, B83 and B).

All 31 December 2020 and 31 December 2019, the intangible assets are as follows:

For the year ended 31 December 2020, the intangible assets are as follows:

(5) Intangible assets

	Land use rights	Software	Contractual right to provide management service	Total
Cost				
31 December 2020	23,622,729	4,610,000		28,232,729
1 January 2020		400,000	2,829,386	3,229,386
31 December 2020	23,602,729	5,039,090	2,829,386	31,471,205
Accumulated amortisation				
31 December 2020	4,752,438	3,213,647		7,966,085
1 January 2020	470,554	60,216	4,207	1,121,477
31 December 2020	5,224,492	3,813,863	49,207	9,087,562
Net book value				
31 December 2020	18,378,237	1,225,227	2,780,179	22,383,643
1 January 2020	18,800,111	1,054,443		19,854,554

2020, the amortisation of intangible assets for the year ended 31 December 2020 was B1,121,477 (2019: B2,677,180). 2020, the amortisation expense of computer software and the acquisition of intangible assets for the year ended 31 December 2020 was B253,627 and B867,800 respectively (2019: B1,733,231 and B883,580 respectively).

All 31 December 2020 and 31 December 2019, the intangible assets are as follows:



Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

16 Provisions for asset impairment (continued)

(6) Provision for asset impairment

	31 December 2019	Provision made	Reversal of provision	31 December 2020
Provision for bad debts of accounts receivable	0,173,228	7,312,656	(6,566,871)	10,529,013
Provision for bad debts of other receivable	0	44,480	0	44,480

Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

16 Note on the components of retained earnings (continued)

(8) Retained earnings

Retained earnings at beginning of the year	200,462,672	182,130,303
After: Profit	34,039,077	30,828,866
Less: Appropriation of profit for the year	(3,403,908)	(3,082,287)
Retained earnings at end of the year	-	(11,323,000)
Retained earnings at end of the year	231,097,841	200,462,672

Management is in agreement with the Board of Directors

Notes to the Financial Statements

For the year ended 31 December 2020
(As approved by the Board of Directors)

16 Revenue and cost of sales (continued)

(9) Revenue and cost of sales (continued)

(a) Revenue and cost of sales from operations

	2020	
	Revenue	Cost
Pharmaceuticals	107,453,075	98,319,580
Revenue and cost of sales from pharmaceuticals	295,840,028	171,088,768
	403,293,103	269,408,348
	€	
	Revenue	Cost
Pharmaceuticals	111,302,285	5,410,727
Revenue and cost of sales from pharmaceuticals	25,712,224	10,752,475
	37109,227	266,171,554

(i) Revenue and cost of sales from pharmaceuticals and revenue and cost of sales from pharmaceuticals in accordance with IFRS

(b) Revenue and cost of sales from operations

	2020	
	Revenue	Cost
Revenue and cost of sales from pharmaceuticals	9,576,790	4,170,935
Revenue and cost of sales from pharmaceuticals	1,481,575	1,450,832
Revenue	160,190	-
Revenue	2,651,529	-
	13,870,084	5,621,767
	€	
	Revenue	Cost
Revenue and cost of sales from pharmaceuticals	11,460,63	6,852,156
Revenue	20,171	-
Revenue	1,30,127	-
	13,576,361	6,852,156



Notes to the Financial Statements

For the year ended 31 December 2020
 (As approved by the Board of Directors)

16 Financial expenses – net (continued)

(10) Financial expenses – net

	2020	2019
Balance at the beginning	16,578,305	7,215,776
Amount of recoverable advances	-	1,841,00
Decrease	16,578,305	9,050,76
Less: Increase	(15,041,897)	(2,427,741)
End of year	258,603	642,578
Net	318,690	473,158
	2,113,701	7,740,71

(11) Expenses by nature

The cost of the services provided, the cost of the administrative services and the cost of the other services are allocated to the cost of the services provided as follows:

	2020	2019
Employee benefits	135,462,152	126,773,342
Material and non-material costs of the operations of the company	131,582,583	122,02,205
Expenses of the company	17,539,174	17,115,40
Expenses of the company	1,346,017	42,156
Amount of the liability	1,121,477	2,677,18
Amount of the expense	7,448,865	7,61,178
Cost of the operations of the company	1,278,086	1,37,226
Other expenses	13,522,767	13,641,04
Other	6,707,463	7,6,646
Other expenses	2,491,617	2,60,386
Other fee	(2,690,386)	Tj-43.4,488.26 -1.556 Td(Others)Tj

Notes to the Financial Statements

For the year ended 31 December 2020
(All amounts in B. S. Rupees in Lakhs)

16 Investment losses/(income)

(12) Investment losses/(income)

	2020	2019
Loss on disposal of investments	8,158,636	632,38
Investment income	34,663	138,95
Net investment losses/(income)	(96,371)	(2,132)
Net investment losses/(income)	-	(824,373)
	8,096,928	(755,472)

Net investment losses/(income) is/(are) due to/(from) the disposal of investments.

(13) Credit impairment losses

	2020	2019
Loss on impairment of accounts receivable	7,312,656	6,623,37
Loss on impairment of other receivables	180,454	7,08,81
Total	7,493,110	14,531,28

(14) Income tax expenses

	2020	2019
Income tax expense based on the provisions	8,472,297	11,10,248
Deferred income tax	2,222,037	(6,4,424)
Total	10,694,334	10,515,824

The reconciliation of the income tax expense based on the applicable tax rate to the provision of income tax expense is as follows:

	2020	2019
Provision	44,733,411	42,58,60
Income tax expense based on applicable rate of 25%	11,183,353	10,64,672
Other provisions of income tax expense	865,025	42,16
Adjustment of income tax expense	(1,354,044)	(563,08)
Income tax expense	10,694,334	10,515,824

Definitions

Agreement	The agreement entered into by the Parties for the purpose of being conducted in accordance with Article 18, 2021.
Article	The article of a provision of the Charter, a statute, or other rule applicable to the Member.
Anti-Corruption	The anti-corruption of the Board.
Beijing Yinan Hospital Co., Ltd.	Beijing Yinan Hospital Co., Ltd. (北京怡寧醫院有限公司), a company established in the People's Republic of China on July 17, 2015, the office of the Party's National People's Congress Representative.

Definitions

- 複製權

Article 21, 21, before the republication of the collection of certain information in the republication of publication
- 臨海康寧醫院有限公司

臨海康寧醫院有限公司 (Lin Hai Kang Ning Hospital Co., Ltd.), according to the provisions of the Republic of China, established on February 2, 1915, of the Republic of China
- 台州市路橋慈寧醫院有限公司

台州市路橋慈寧醫院有限公司 (Taizhou City Luqiao Cining Hospital Co., Ltd.), according to the provisions of the Republic of China, established on October 12, 1916, of the Republic of China
- 台州市路橋怡寧醫院有限公司

台州市路橋怡寧醫院有限公司 (Taizhou City Luqiao Yining Hospital Co., Ltd.), according to the provisions of the Republic of China, established on October 12, 1916, of the Republic of China
- 國家醫療保險

the National Health Insurance Act of the Republic of China
- 國家醫療保險法

the National Health Insurance Act of the Republic of China
- 南京怡寧醫院有限公司

南京怡寧醫院有限公司 (Nanjing Yining Hospital Co., Ltd.), according to the provisions of the Republic of China, established on October 12, 1916, of the Republic of China

Definitions

青田康寧醫院 (Qingtian Kangning Hospital)	青田康寧醫院有限公司 (Qingtian Kangning Hospital Co., Ltd. (青田康寧醫院有限公司)), a wholly owned subsidiary of the Company, established on April 1, 2011, of the People's Republic of China.
衢州怡寧醫院 (Quzhou Yining Hospital)	衢州怡寧醫院有限公司 (Quzhou Yining Hospital Co., Ltd. (衢州怡寧醫院有限公司)), a wholly owned subsidiary of the Company, established on October 15, 2015, of the People's Republic of China.
報告期 (Reporting Period)	December 31, 2016
報告期 (Reporting Period)	December 31, 2016
監事會 (Board of Supervisors)	監事會 (Board of Supervisors of the Board)
B	人民幣 (Renminbi)
SF	《證券發行與承销管理辦法》 (Article 571 of the Law of the People's Republic of China on Securities Issuance and Underwriting)
State()	State()指中華人民共和國，包括香港、澳門及台灣 (State() refers to the People's Republic of China, including Hong Kong, Macau and Taiwan)
State of e()	State of e() of the State()
深圳怡寧醫院 (Shenzhen Yining Hospital)	深圳怡寧醫院有限公司 (Shenzhen Yining Hospital Co., Ltd. (深圳市怡寧醫院有限公司)), a wholly owned subsidiary of the Company, established on September 22, 2014, of the People's Republic of China.
審計委員會 (Audit Committee)	審計委員會 (Audit Committee of the Board)
子公司 (Subsidiary)	指根據《中華人民共和國公司法》 (Article 622 of the Law of the People's Republic of China)
比亞沙芬 (Bifosfen)	指根據《中華人民共和國公司法》 (Article 622 of the Law of the People's Republic of China)
特別委員會 (Special Committee)	特別委員會 (Special Committee of the Board)
特別委員會 (Special Committee)	特別委員會 (Special Committee of the Board)
特別委員會 (Special Committee)	特別委員會 (Special Committee of the Board)

Definitions

- 台州康寧醫院 (Opiaa) 台州康寧醫院 (Opiaa Co., Ltd. (台州康寧醫院有限公司), a company established in the People's Republic of China on Feb. 16, 2016, of the People's Republic of China.
- 溫嶺南方精神疾病專科醫院 (Opiaa) 溫嶺南方精神疾病專科醫院 (Opiaa Co., Ltd. (溫嶺南方精神疾病專科醫院有限公司), a company established in the People's Republic of China on Feb. 18, 2016, of the People's Republic of China.
- 溫州慈寧醫院 (Opiaa) 溫州慈寧醫院 (Opiaa Co., Ltd. (溫州慈寧醫院有限公司), a company established in the People's Republic of China on Feb. 25, 2016, of the People's Republic of China.
- 溫州國大投資 (Opiaa) 溫州國大投資 (Opiaa Co., Ltd. (溫州國大投資有限公司), a company established in the People's Republic of China on Feb. 29, 2012, of the People's Republic of China.
- 燕郊輔仁中西醫結合醫院 (Opiaa) 燕郊輔仁中西醫結合醫院 (Opiaa of Yanjiao Fuxin TCM and Western Medicine Integrated Hospital) is a hospital established in accordance with the relevant laws and regulations of the People's Republic of China on Feb. 15, 2015. It is located in the Sanyhe Yanjiao Fuxin TCM and Western Medicine Integrated Hospital, Beijing. Opiaa of Yanjiao Fuxin TCM and Western Medicine Integrated Hospital (燕郊輔仁中西醫結合醫院) is a hospital established in accordance with the relevant laws and regulations of the People's Republic of China on Feb. 15, 2015.
- 杭州耶利米 (Opiaa) 杭州耶利米 (Opiaa of Hangzhou Yelimi Information Technology Co., Ltd. (杭州耶利米信息科技有限公司), a company established in the People's Republic of China on Feb. 27, 2018, of the People's Republic of China.
- 怡寧心理互聯網醫院 (溫州) (Opiaa) 怡寧心理互聯網醫院 (溫州) (Opiaa (Yining) Co., Ltd. (怡寧心理互聯網醫院(溫州)有限公司), a company established in the People's Republic of China on Feb. 20, 2019, of the People's Republic of China.
- 永嘉康寧醫院 (Opiaa) 永嘉康寧醫院 (Opiaa Co., Ltd. (永嘉康寧醫院有限公司), a company established in the People's Republic of China on Feb. 12, 2012, of the People's Republic of China.
- 樂清康寧醫院 (Opiaa) 樂清康寧醫院 (Opiaa Co., Ltd. (樂清康寧醫院有限公司), a company established in the People's Republic of China on Sep. 3, 2013, of the People's Republic of China.
- percent

溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.